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Abstract  
Icosahedral carboranes are highly stable boron-carbon clusters that have been used as 
unique pharmacophores in biological active compounds. Carboranes have promising 
applications in Boron Neutron Capture Therapy (BNCT), a technique based on the 
nuclear capture of neutrons by 10B to produce high energy particles that selectively 
destroy tumors without affecting healthy tissues. The application of BNCT depends on 
the availability and selectivity of boron compounds which bind receptors in the tumors. 
The vitamin D nuclear receptor (VDR) is a potential target for cancer therapy, because 
it is expressed in many tumors and its ligand, 1α,25-dihydroxyvitamin D3 (1,25D or 
calcitriol), can induce anticancer actions. To combine these properties with BNCT 
application, new VDR agonists based on the skeleton of the hormone 1,25D that 
contained ortho, meta and para-carboranes at the end of its side chain were designed. 
Docking studies revealed several promising carborane-containing calcitriol analogs. 
Three analogs were chosen as synthetic targets. The synthetic approach features a 
Pd-catalyzed construction of the triene system and an SN2 displacement of a tosylate 
group by a carboranyllithium reagent to afford three carborane-containing vitamin D 
analogs.  
 
Key words: Carboranes, vitamin D, 1,25D, BNCT, analogs, docking, organic 
synthesis, Suzuki-Miyaura cross-coupling.  
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Resumo 
Carboranos icosaédricos são complexos de boro-carbono altamente estáveis que têm 
sido usados como farmacóforos únicos em compostos biologicamente ativos. Os 
carboranos têm aplicações promissoras na Terapia de Captura de Neutrões pelo Boro 
(BNCT), uma técnica baseada na captura nuclear de neutrões pelo 10B para produção 
de partículas de alta energia que destroem selectivamente tumores sem afetar tecidos 
saudáveis. A aplicação da BNCT depende da disponibilidade e selectividade dos 
compostos de boro que ligam a recetores tumorais. O recetor nuclear da vitamina D 
(VDR) é um potencial alvo para a terapia cancerígena, porque é expresso em vários 
tumores e o seu ligando, 1α,25-dihidroxivitamina D3 (1,25D ou calcitriol), é capaz de 
induzir ações anticancerígenas. De modo a combinar estas propriedades com a 
aplicação da BNCT, foram desenhados novos agonistas do VDR cuja estrutura se 
baseia no esqueleto da hormona 1,25D que contivessem ortho, meta e  
para-carboranos no final da cadeia lateral. Estudos de docking revelaram promissores 
análogos do calcitrol com carboranos na cadeia lateral. Três compostos foram 
escolhidos como objetivo sintético. A abordagem sintética engloba a construção do 
sistema triénico catalisada por paládio e a substituição de um grupo tosilato por um 
reagente carboranilítio para se obter três análogos da vitamina D com unidades 
carborânicas diferentes.  
 
Palavras-chave: Carboranos, vitamina D, 1,25D, BNCT, análogos, docking, síntese, 
cross-coupling de Suzuki-Miyaura  
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Introduction 
1. VITAMIN D3 
Vitamin D3, through its hormonal form, the 1α,25-dihydroxyvitamin D3 (calcitriol, 1,25D,  
Fig. 1) is essential for the maintenance of health. Indeed, calcitriol influences a large 
range of physiological processes, including calcium and phosphate metabolism, bone 
maintenance, cellular proliferation, differentiation, apoptosis and immune regulation.1  
 
Fig. 1. Structure of vitamin D3 and calcitriol 
Calcitriol plays an important role in several pathologies, like psoriasis, multiple 
sclerosis, rheumatoid arthritis, diabetes and cancer, which has increased the interest in 
the development of vitamin-D based therapies.2 
1.1. Structure and nomenclature of vitamin D 
The structure and mode of action of calcitriol are closely related to that of classical 
steroid hormones, like cortisol, testosterone and progesterone (Fig. 2).  
             
Fig. 2. Structure of calcitriol and other steroid hormones 
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The structure of steroids has a common cyclopentaneperhydrophenanthrene skeleton 
composed of four rings (A, B, C and D). The cleavage of one of these rings is designed 
by the term “seco”. The vitamin D is classified as a secosteroid because its skeleton 
derives from the photochemical cleavage of the C9-C10 bond of the B ring of a steroid 
precursor.  
The vitamin D and its metabolites are named and numbered according to their steroid 
precursor. They have more conformational flexibility than other steroid hormones, due 
to the presence of:  
1) a triene system that can rotate around the C6-C7 bond, to afford two planar 
conformations: 6-s-cis and 6-s-trans (Fig. 3B); 
 2) a rotatable side chain with 5 single C-C bonds, that can freely rotate 360 º (Fig. 3C);  
3) an A-ring that can undergo a chair-chair interconversion, which changes the 
orientation of the 1α and 3β hydroxyl groups between the equatorial and axial 
orientation (Fig. 3D).3  
 
Fig. 3. Conformational flexibility of the triene system, side chain and the A ring of calcitriol 
These highly mobile parts are linked to a rigid CD-ring system.  
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1.2. Biotransformation of vitamin D 
The predominant form of vitamin D in humans is vitamin D3 , which can be obtained 
through diet, dietary supplements or by endogenous production from  
7-dehydrocholesterol (7-DHC, Scheme 1).4  
The biosynthesis of vitamin D3 is initiated in the skin by the photochemical ring opening 
of 7-DHC under UVB radiation (Scheme 1). The resulting previtamin D3 undergoes a 
sigmatropic rearrangement [1,7]-H to afford the vitamin D3.
4-5 
 
Scheme 1. Biosynthesis of vitamin D3 in the skin 
Vitamin D3 goes through two enzymatic transformations to give the active form, 
calcitriol. These two hydroxylations occur first in the liver and then in the kidneys or 
extra-renal sites (Scheme 2).  
 
Scheme 2. Biological activation of vitamin D3 
The first hydroxylation is predominantly catalyzed by vitamin D-25-hydroxylase 
CYP2R1.2 The resulting 25-hydroxyvitamin D3, 25(OH)D3 is the main circulating form of 
the vitamin in the serum. The generated 25(OH)D3 associates with vitamin D binding 
protein (DBP),6 to reach the kidneys or extra-renal sites.2  
A cytochrome P450 enzyme, CYP27B1, is responsible for the second hydroxylation, in 
the 1α position, to produce the hormonal form of vitamin D, calcitriol.7  
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In extra-renal tissues, locally synthetized 1,25D works in an autocrine or paracrine 
manner, while calcitriol synthetized in the kidneys performs its functions in an 
endocrine manner, via association with DBP in the serum.  
Calcitriol also undergoes metabolic degradation, mainly through an inactivating  
24-hydroxylation, which is catalyzed by another cytochrome P450 enzyme, CYP24A1 
(Scheme 3).2  
 
Scheme 3. Catabolism of calcitriol 
This enzyme catalyzes three consecutive oxidations of calcitriol at C-24 and C-23, 
leading to the formation of more water-soluble and less active metabolites. This ends 
with the production of the inactive calcitroic acid, which can easily be eliminated 
through urine.5 
2. MECHANISM OF ACTION OF CALCITRIOL 
Vitamin D, in consonance with other nuclear steroids, induces both genomic and  
non-genomic actions. The slow classical genomic functions of vitamin D occur via 
transcription activation triggered by nuclear vitamin D receptor (VDR). The fast  
non-genomic actions of the hormone involve second messengers generated by 
membrane-initiated signaling pathways.  
2.1. Genomic actions of calcitriol 
The genomic actions of calcitriol mediate hormone secretion, calcium and phosphate 
homeostasis and even regulate cellular proliferation, differentiation and apoptosis. 
These actions involve binding of calcitriol to the vitamin D receptor (VDR). Since the 
discovery of this nuclear receptor, in 1974,8 a lot of explorative studies were 
undertaken to collect information on the VDR’s distribution, structure and mechanism of 
action.  
FCUP | ICBAS | USC 
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The VDR (427 amino acids, 48 kDa) is a member of the superfamily of ligand-activated 
nuclear receptors that include receptors for steroid, retinoid and thyroid hormones. 
VDR is expressed in a multitude of tissues, including malign cells from breast, prostate 
and colon cancer, as well as acute myeloid leukaemia.9 This receptor modulates gene 
expression by association with its ligand, calcitriol, and its heterodimer partner, retinoid 
X receptor (RXR). 
Structurally, it is composed of six regions (A to F), numbered from the N-terminal 
extension. Additionally, VDR is also divided in two distinct domains, based on 
functional aspects: a DNA binding domain (DBD) and a ligand binding domain (LBD) 
(Fig. 4). These domains are bound together by an unstructured linker. 
 
 
Fig. 4. Schematic representation of the structure of human VDR 
The crystal structure of the entire VDR is not yet available. However, the crystal 
structures of the individual domains (DBD and LBD) have been published and are 
useful in the study of the function of calcitriol and VDR.10-11  
The DBD is a highly conserved domain that contains two zinc fingers. Structurally, this 
domain corresponds to the C region of the protein. This domain anchors VDR to 
specific DNA sequences, the vitamin D response elements (VDREs), through the zinc 
fingers.10 These VDREs are usually repeats of hexanucleotides with a spacing of 3 
nucleotides between half sites, called DR3 VDR motifs. 
The LBD is a highly variable C-terminal domain that corresponds to the E and F 
regions of the receptor. This domain confers the VDR high specificity and affinity 
towards its ligand, calcitriol.  The three dimensional structures of the modified human, 
rat and zebrafish VDR(LBD) have been established, with the receptor bound to 
calcitriol and other ligands.11-13 These structures show that the VDR(LBD) structure is 
comprised of 13α helices sandwiched in 3 layers and 3 stranded β sheets that, 
together, form a highly hydrophobic ligand binding pocket (Fig. 5A).11 This ligand 
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binding cavity is large (697 Å) and calcitriol only occupies 56% of the total volume. 
Indeed, there is additional space around the aliphatic chain and near position C2 of the 
A-ring.14  
The 1,25D is anchored to this binding pocket by six hydrogen bonding interactions  
(Fig. 5B).11 In the human VDR(LBD), the C1α-OH of calcitriol interacts with Ser237 and 
Arg274, while the C3β-OH binds to Tyr143 and Ser278. The C25-OH group at the side 
chain of calcitriol interacts with His305 and His397.  
 
Fig. 5. A) Crystal structure of the 1,25D-LBD-VDR complex; B) Representation of polar interaction in the ligand pocket 
of VDR  (PDB code: 1DB1) 
Calcitriol is also anchored to the LBD by non-polar interactions, which greatly influence 
the conformation adopted by this hormone inside the binding pocket (Fig. 6). The 
conjugated triene system of the ligand accommodates a trans conformation tightly fitted 
in a hydrophobic channel made of Ser275 and Trp286 on one side and Leu233 on the 
other.  
 
Fig. 6. Representation of non-polar interaction between the residues of LBD-VDR and calcitriol (PDB code:1DB1) 
A B 
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The aliphatic side chain of calcitriol is surrounded by hydrophobic residues and adopts 
an extended conformation parallel to the C13-C18 bond. The methyl group of the side 
chain of calcitriol makes two important van der Waals contacts with residues from the 
helix 12 (H12), Val418 and Phe422 (Fig. 6). 
This interaction of calcitriol with the residues of the C-terminal H12 is particularly 
important for interaction of VDR with transcriptional machinery proteins. This helix 
contains a seven amino acid region called the ligand dependent activation function  
(AF-2) that acts as a molecular switch in a ligand-dependent manner.  
Regarding the mechanism of action of VDR, it is known that this receptor induces gene 
expression via association with calcitriol, RXR and co-activators (Scheme 4).  
 
Scheme 4. Mechanism of genomic actions of calcitriol 
Calcitriol or 25(OH)D3 are transported in the blood stream by DBP and enter target 
cells by passive diffusion. Inside the cell, 25(OH)D3 is locally hydroxylated to calcitriol 
by CYP27B1. Calcitriol interacts with cytoplasmic VDR, inducing the conformational 
shift of helix 12. This molecular switch closes over the hormone in a mouse-trap 
mechanism that anchors calcitriol to VDR and facilitates the formation of protein 
interaction interfaces.  
Upon calcitriol binding, VDR is rapidly translocated to the nucleus, where it forms a 
heterodimer with another nuclear receptor, RXR, to become transcriptionally active. 
Once the VDR-RXR heterodimer is formed, it associates with VDREs and recruits 
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various coregulatory complexes to target gene promotors,15-16 resulting in activation of 
target gene expression. 17  
These highly specific changes in gene expression combine to orchestrate complex and 
tissue-specific responses. Indeed, using transcriptome-wide analysis, calcitriol was 
found to modulate the expression of 229 genes.18  
2.2. Non-genomic actions of calcitriol 
Besides the classical genomic actions, it is presently recognized that calcitriol also 
exerts fast, non-genomic actions. These actions work in a nuclear VDR independent 
manner, as they involve membrane-triggered processes. The mechanism of  
non-genomic action is gradually being unraveled and is thought to impact a wide range 
of cellular processes,19 such as transcaltachia, insulin secretion and phospholipid 
metabolism.15 
These rapid responses involve two distinct membrane-bound receptors: the membrane 
associated rapid response steroid (MARRS), also known as Pdia3,20 and  
membrane-bound VDR (Scheme 5). Although VDR is typically a nuclear receptor, it 
has been co-localized in caveolae-enriched plasma membranes, through association 
with a scaffolding protein, caveolin-1 (Cav-1).21-23 MARRS also binds to Cav-1 in these 
caveolae. The presence of Cav-1 is then essential for the non-genomic actions of 
1,25D.  
 
Scheme 5. Mechanism for the non-genomic actions of calcitriol 
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Once VDR or MARRS are associated with Cav-1, calcitriol is able to bind to either one 
of these receptors. The interaction between calcitriol and the VDR/Cav-1 complex or 
the MARRS/Cav-1 complex triggers the initiation of different signaling pathways, 
through a not fully understood mechanism. Presumably, the binding of calcitriol to 
either of these complexes leads to the activation of G proteins or non-receptor tyrosine 
kinases, like Src kinase (c-Src),24 which  leads to the initiation of different signaling 
cascades. These signaling pathways are summarized in Scheme 5 and are responsible 
for the induction of changes in protein activity and even changes in gene expression, in 
a cell-type, cell-stage and gene specific manner.19, 25  
3. BIOLOGICAL ACTIVITY OF CALCITRIOL 
Calcitriol, through both genomic and non-genomic mechanisms, is responsible for a 
multitude of biological functions that are divided in classic and non-classic actions. The 
role of calcitriol in the maintenance of calcium levels in extracellular fluids is a classic 
function of this hormone. On the other hand, the non-classic biological functions of 
calcitriol include the regulation of cellular proliferation and differentiation and 
modulation of the immune response.  
3.1. Calcium and Phosphate Homeostasis 
The maintenance of physiologic levels of extra and intracellular levels of calcium and 
phosphate is a highly complex and regulated process. This homeostasis is dependent 
on different enzymes and hormones, and involves a coordinated action of the 
parathyroid glands, kidneys, intestine and bone.  
Calcitriol is responsible for the absorption of dietary calcium and phosphate from the 
gastrointestinal tract, the renal calcium reabsorption and the calcium release from bone 
(Scheme 6). These effects are regulated by a negative feedback mechanism, in which 
calcitriol inhibits the synthesis and secretion of the parathyroid hormone (PTH).  
The parathyroid glands are responsible for the synthesis of the PTH. In response to low 
calcium levels (hypocalcemia), the glands secrete PTH, which stimulates the activation 
of renal CYP27B1 and renal degradation of CYP24A1 mRNA, leading to an increase of 
calcitriol production (Scheme 6).26-28  
The calcium and phosphate homeostasis is also regulated by fibroblast growth  
factor 23 (FGF23).26 The production of FGF23 by osteoblasts and osteocytes in the 
bone is stimulated by an increase of calcitriol levels. FGF23 participates in the 
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regulation of calcium and phosphate homeostasis, as it inhibits the synthesis and 
secretion of PTH and decreases renal CYP27B1 in response to  elevated calcitriol and 
phosphate levels.29 
 
Scheme 6. Schematic illustration of the effects of calcitriol on the calcium and phosphate homeostasis 
These classic actions of calcitriol can be applied clinically, through the use of calcitriol 
and its analogs in the control of secondary hyperthyroidism in renal failure and 
osteoporosis.  
3.2. Cellular Differentiation and Proliferation 
Calcitriol is known to have anti-proliferation and pro-differentiation effects in several cell 
types mainly through a genomic mechanism.9  
Regarding its anti-proliferative function, calcitriol is known to increase the expression of 
cyclin-dependent kinase inhibitors (CDKIs) p21 and p27. These CDKIs are responsible 
for regulating the transition from the G1 phase (responsible for cell growth) to the S 
phase (responsible for DNA replication) of the cell cycle. Calcitriol increases the 
expression of these inhibitors, which prevents the progression of the cell cycle to the S 
phase, thus inhibiting cell proliferation.30 
Bone 
FCUP | ICBAS | USC 
Introduction 
13 
Calcitriol has also been found to induce differentiation in several cells, from 
keratinocytes to breast and prostate cancer cells.31-33 
Given these functions, it was postulated that calcitriol and its analogs could have 
applications in cancer therapy. Additionally, taking into account that calcitriol induces 
differentiation and inhibits proliferation in keratinocytes, several calcitriol analogs are 
commercially available for the treatment of moderate forms of psoriasis.32  
3.3. Immune System Regulation 
Calcitriol plays a role in immune regulation because it can be synthesized in and have 
effect on T cells,34-35 B cells36 and antigen presenting cells (APCs).37-38 Therefore, 
calcitriol has immunomodulatory effects that could be used in the treatment of 
autoimmune diseases. Indeed, vitamin D-based therapies have been applied in the 
control of autoimmune disorders like systemic lupus erythematosus, rheumatoid 
arthritis, multiple sclerosis and type I diabetes.  
3.4. Transcaltachia 
Transcaltachia refers to the non-genomic rapid (2-10 minutes) stimulation of intestinal 
calcium transport. Although this process can have a useful role in calcium 
homeostasis, it greatly hinders the application of vitamin D-based therapies. Calcitriol 
and some of its analogs have poor clinical application due to side effects like 
hypercalcemia, mainly caused by transcaltachia. As such, there has been a major 
effort to synthesize non-calcemic calcitriol analogs.39-41  
3.5. Pharmacological Endeavors 
The elucidation of the crystallographic structure of the LBD of VDR11 has facilitated the  
rational design of new analogs. 
Although more than 3500 analogs have been synthesized, only a few, are currently 
commercially available and are clinically applied (Fig. 7).42 Some of these drugs are 
used in the treatment of psoriasis, osteoporosis, multiple sclerosis, and bone and 
pancreatic cancer.  
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Fig. 7. Commercially available calcitriol analogs 
The design of innovative VDR ligands with unique functional groups was propelled. 
This search for interesting novel leads has unveiled the great promise of a previously 
unexplored element in drug design: boron.  
 
4. CARBORANES 
Recently, the pharmaceutical industry and an increasing number of medicinal 
chemistry researchers are using boron as a substitute for carbon in different classes of 
drug molecules. Molecules with boron atoms are expected to be less complex than 
their carbon counterparts, reducing costs in drug research and manufacturing. Also, the 
possibility of new interactions of these molecules with biological targets unaffected by 
classical ligands makes the use of these boron moieties very alluring. A  
boron-containing drug, Velcade® is commercialized (Fig. 8) and several others have 
entered human clinical trials.43-45  
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Fig. 8. Commercially available boron-containing drug Velcade 
Boron tends to form compounds with covalent B-H and B-B bonds called boranes. 
These boranes exist preferentially in polyhedral clusters with globular architectures.46  
One important class of polyhedral borane clusters are carboranes, in which two BH- 
units of the closo-B12H12
2− cluster are replaced by 2 CH vertices.   
The recent interest in applying carboranes to medicinal chemistry has arisen due to 
their particular electronic properties, geometry and versatility, together with the newest 
development in carborane chemistry.   
4.1. Structure of carboranes 
Carboranes, or carbaboranes, are polyhedral carbon-containing boron clusters. Among 
these, the dicarba-closo-dodecaboranes (C2B10H12) are the most extensively studied 
and are usually referred to as simply carboranes. They are rigid molecules with an 
icosahedral structure, containing 10 BH vertices and 2 CH vertices. The carbon and 
boron atoms are hexacoordinated to compensate the low electron density, forming 20 
triangular faces.  
Carboranes exist in three isomeric forms, depending on the positioning of their 2 CH 
vertices: ortho- (or 1,2-), meta- (or 1,7-) and para- (or 1,12-) carborane (Fig. 9). 
 
Fig. 9. Representation of the three closo-carborane isomers 
The ortho- and meta-carboranes have C2v symmetry, while the p-isomers have a D5d 
symmetry. The overall size and the core volume of carboranes slightly decrease from 
ortho- to para-carboranes, though these differences are not significant. Generally, the 
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size and volume of carboranes is similar to that of adamantane and almost twice the 
spherical volume occupied by a phenyl ring (Fig. 10).  
 
Fig. 10. Representation of an o-carborane, adamantane and benzene 
4.2. Electronic Properties 
Carboranes have non-classical bonding interactions, resulting in a very complex overall 
electronic structure.  They have 26 electrons (2n+2 skeletal e-) divided between the 12 
vertices, which are three-dimensionally delocalized, meaning that carboranes are 
characterized as three-dimensional aromatic compounds. As such, these compounds 
are not easily defined by usual organic bond diagrams and the bonds between atoms 
represent only geometry.  
In terms of electronegativity, the carbon and hydrogen atoms are more electronegative 
than the boron atoms, which explain some of the carborane properties. Additionally, 
boron-carbon bonds are stronger than carbon-carbon bonds, meaning that the more 
stable isomer has carbon atoms in nonadjacent positions.  
4.3. Hidrophobicity 
In terms of hydrophobicity, carboranes are usually more hydrophobic than their carbon 
counterparts. The hydrogens atoms of the BH vertices have partial negative charges, 
making them similar to hydrides, which explain the high hydrophobicity of carboranes.  
The different carboranes isomers show differences in hydrophobicity, as the 
hydrophobicity increases in the order ortho, meta to para isomers.  
The hydrophobicity of carboranes and carborane-containing drugs can be fine-tuned by 
choosing to substitute the different vertex positions. Free CH groups of carboranes, 
which are acidic, decrease the hydrophobicity of the carborane. On the contrary,  
C-substituted carboranes are more hydrophobic. B-substituted carboranes are less 
hydrophobic than their counterparts.  
 
FCUP | ICBAS | USC 
Introduction 
17 
4.4. Acidity 
The protons of the C atoms are relatively acidic, depending on the cluster isomer. The 
acidity of the carborane protons decreases in the order ortho-, meta- to  
para-carborane. Organometallic bases, such as nBuLi can remove a proton from C-H, 
generally creating a carboranyl nucleophile. B or C substituents influence both the 
acidity of the carborane protons and the acidity of the cluster protons.  
4.5. Molecular interactions 
The outer sphere of carboranes is composed of hydrogens, meaning that these 
hydrogen atoms are the main mediators of intermolecular interactions in unsubstituted 
carboranes.  
Carboranes have two different types of hydrogen atoms: acidic hydrogens from CH 
groups and hydride hydrogens from BH groups. 
These two types of hydrogen atoms are involved in distinct intermolecular interactions  
(Fig. 11). The CH moieties form classic hydrogen bonds (C-H • • •X) with 
electronegative atoms (O, N, S or F). 
 
Fig. 11. Two-dimensional representation of intermolecular interactions of o-carborane 
On the other hand, the hydride BH units can form dihydrogen bonds (B-H • • •H-X) with 
protons bound to electronegative atoms. These interactions occur with small 
molecules, as well as in the active site of proteins and enzymes, which makes 
carboranes very interesting pharmacophores.  
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4.6. Chemistry  
The ortho-carborane can be obtained by reaction of decaborane (B10H14) with 
acetylenes in the presence of a Lewis base (Scheme 7). Thermal isomerization of 
ortho-carboranes, in an autoclave, leads first to the meta isomer (465-500 ºC) and 
finally to the para isomer (615-700 ºC). 
These carboranes are chemically stable and are inert to water and atmospheric 
oxygen.  
 
Scheme 7. Synthesis of ortho, meta and para-carboranes 
They can be derivatized on the boron vertices, by electrophilic substitution; and on the 
carbon vertices, by removal of acidic CH protons with strong bases.  
Carboranes can undergo metalation with nBuLi to afford the carboranyllithium 
derivative, which can react with an electrophile to form a C-substituted carborane.  
Thus, from a synthetic point of view, carboranes are interestingly versatile and can be 
used to create wide libraries of pharmacophores for distinct purposes.  
4.7. Boron Neutron Capture Therapy (BNCT) 
As most of their properties are prone to be fine-tuned, carboranes may prove to be 
superior bioactive molecules than their organic counterparts. Also, these  
closo-carboranes are great candidates for boron neutron capture therapy (BNCT). 
This experimental cancer treatment uses boron compounds in the treatment of several 
cancers, mainly glioblastoma multiform (GBM). In this case, clinical studies have 
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demonstrated that BNCT is not only safe but at least as efficient as conventional 
radiotherapy.  
This technique is based on the nuclear capture of neutrons by 10B to produce high 
energy particles that selectively destroy tumors without affecting healthy tissues. It 
works as a two-component, or binary, therapy, since it uses two independent key 
components: the boron clusters and low energy thermal neutrons.  
When irradiated, the non-radioactive 10B isotopes present in boron clusters capture the 
low-energy neutrons and then  fissure into kinetic energy and into high linear energy 
transfer (LET) particles: alpha particles (two protons and two neutrons) and lithium 
ions.47 These high LET particles have path-lengths of about 10 µm, roughly the 
diameter of a single cell, which makes the cytotoxic effect largely confined to cells that 
accumulated the boron compound (Fig. 12). 
 
Fig. 12. Selective neutron capture of neutrons by 
10
B in a tissue
48
 
The application of BNCT depends on: 
1) the selectivity of the compounds for a target highly expressed in tumors, as that 
would mean that surrounding healthy tissue would be less affected; 
2) the number of boron atoms accumulated in tumor cells, as a high number 
accumulated of boron atoms in tumor cells would increase the probability of 
neutron capture events.  
As such, highly selective compounds that contain boron clusters like carboranes  
(1 moiety = 10 B) should be very efficient BNCT agents. Indeed, carboranes are 
currently being studied for that purpose, as they are being used in the synthesis of 
novel DNA metallointercalators that could bind to tumor cell DNA and of  
hypoxia-selective agents that could enter low-oxygen regions in tumors.45  
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Another tumor-selective target that should be considered for BNCT therapy is the VDR. 
The VDR is a good target for selective application of BNCT because its expression is 
increased in some tumors, such as breast cancer. The next obvious step is, then, the 
design of VDR agonists that contain closo-carboranes, an endeavor explored in this 
work. 
5. BACKGROUND  
Recently, an unique secosteroid vitamin D analog with an o-carborane moiety at the 
side chain (Fig. 13A) has been designed, synthetized and biologically tested.49 This 
compound (RO) binds efficiently to VDR and induces similar biological activities with 
reduced calcemic effects, in comparison to 1,25D.  
 
 
Fig. 13. A) Representation of analog RO. B) Structure of the binding pocket of zVDR LBD bound to analog RO. 
Analog RO was crystallized in the zebra-fish wild-type VDR LBD at a 2.4 Å resolution 
(Fig. 13B). This compound adopts the canonical active conformation of the  
calcitriol-VDR complex. The carborane unit mimics the interaction of the C25-OH in the 
binding pocket of VDR. It is even postulated that the carborane cage interacts with 
His333 and His423 (His305 and His397 in human VDR, respectively) through  
non-conventional dihydrogen bonds (BH•••HN).  
The synthesis of analog RO was accomplished in 9 steps and is illustrated in  
Scheme 8.  
The ortho-carborane moiety of analog RO was formed late in the synthesis, to avoid 
complications regarding carborane chemistry and characterization. The carborane was 
B A 
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introduced in the side chain by reaction of an alkyne with decaborane (B10H14), in the 
presence of N,N-dimethylaniline.  
These results proved that carborane-containing vitamin D analogs can be biologically 
active and have less calcemic effects than calcitriol itself. As such, the synthesis of 
analog RO paved the way for the rational design of new  
carborane-containing vitamin D analogs that could have medical and pharmaceutical 
application.  
 
Scheme 8. Synthesis of target carborane RO. Reagents and conditions: a) pTsCl, py, 0 ºC, 12 h; b) Et2O/THF, Li2CuCl4, 
THF, -78 ºC / rt, 12 h; c) PDC, CH2Cl2, rt, 5 h; d) (Ph3PCH2Br)Br, KO
t
Bu in THF, tol, -15 ºC / rt, 3 h; e) 
t
BuLi, B(O
i
Pr)3, 
pinacol, tol/THF, -78 ºC / rt, 4 h; K3PO4 (2 M), PdCl2(PPh3)2, THF, 2 h;  (g) K2CO3, MeOH, rt, 14 h; (h) PhNMe2, tol, 
decaborane (B10H14), 110 ºC, 1 h; (i) HF (48%), CH2Cl2/CH3CN (2 : 1), rt, 12 h.  
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Objectives 
This work was developed to improve the properties of analog RO and explore potential 
application of other carborane-containing calcitriol analogs in BNCT. As such, the 
design and synthesis of new carborane analogs was planned. The objectives of this 
work were:  
1) Docking of new carborane-containing vitamin D analogs into the  
1,25D-VDR(LBD) complex to study their in silico affinity for the VDR.  
2) Synthesis of the target analogs A1, A17 and A33 (Fig. 14). 
 
 
Fig. 14. Target compounds  
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Results and Discussion 
1. CHAPTER I: Design and Docking of carborane-containing vitamin 
D analogs 
1.1. Design of carborane-containing vitamin D analogs 
New carborane-containing calcitriol analogs were designed and docked into the LBD of 
VDR (Fig. 15). In order to find the ligands that bind better to this receptor, several 
different parameters were investigated: 1) the carborane isomer connected to the side 
chain (ortho-, meta- or para-carborane); 2) the C-substituents attached to the 
carborane unit (R groups); 3) the length of the side chain connecting the carborane unit 
to the CD-ring system (n=1, n=2 or n=3). 
 
Fig. 15. Representation of carborane-containing analogs to analyze by docking in human VDR 
Justification for the choice of parameters: 
 
1) It is unknown whether the slight differences in electronic properties, 
hydrophobicity and acidity46 between carborane isomers could influence the 
analogs’ binding affinity. The orientation of the attached R groups could also 
affect the binding. 
2) Analogs with different R groups could interact differently with the VDR, thus 
altering their binding affinity. The size and nature of the R groups were 
expected to have an impact on the chemical and physical properties of each 
analog inside the VDR.  
3) Given the size of the carborane moiety49 and depending on the size of the 
different R groups attached, the length of the side chain (n= 1, 2 or 3) could 
influence the analogs’ binding affinity for the VDR.  
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1.2. Building of the proposed carborane-containing vitamin D analogs 
The ligands were built using the PyMol program.50 The vitamin D part was obtained 
from the crystal structure of the complex of 1,25D-hVDR LBD (PDB code: 1DB1).11 The 
carborane cage part of the ligands was obtained from the crystal structure of the 
corresponding ortho (PDB code: 5E7V),49 meta (PDB code: 4MDL)51 and  
para-carboranes (PDB codes: 3VJS).52 The ligands were further treated by adding 
hydrogen atoms and checking atom valence using Chem3D. Energy minimization of 
the ligands was performed using the MM2 function of Chem3D. 
1.3. Docking of the proposed carborane-containing vitamin D analogs 
Docking studies to predict the affinity of the new ligands for the VDR were carried out 
using the GOLD program (version Suite 5.2). A modified crystal structure (addition of 
hydrogens, reconstitution of gaps and correction of His tautomers) of the complex 
between 1,25D-hVDR(LBD) was chosen as protein (PBD code: 1DB1).11 
The Ligand Binding Pocket of the mutant LBD was defined as Binding Site with the 
automatic active-site detection on, and the radius was set to 10 Å. The conformations 
for each ligand in the active site of the protein were sampled using a genetic  
algorithm (GA). The ligands were docked in 25 independent genetic algorithm (GA) 
runs, for each of which a maximum of 125000 GA operations were performed on a 
single population of 100 individuals. Operator weights for crossover, mutation, and 
migration in the entry box were used as default parameters (95, 95, and 10, 
respectively), as well as the hydrogen bonding (4.0 Å) and van der Waals (2.5 Å) 
parameters. The different poses were ranked according to the force-field-based 
CHEMPLP scoring function and GoldScore was used as a re-scoring function. The  
3 best solutions for each ligand were obtained with an associated score and these 
results were compared with the solutions for 1,25D. 
1.4. Docking Results  
The best obtained poses for each ligand were analyzed in terms of score, adopted 
conformation inside the receptor and interactions with the different residues.  
In appendix 1 (page 83), the chosen conformation for each ligand was superimposed to 
the natural ligand 1,25D (represented in grey) into the ligand binding pocket of VDR.  
The interactions with His305 and His397 are shown for all analogs. The interactions 
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between the C3-OH and C1-OH of the analogs and Tyr143, Ser237, Arg274 and 
Ser278 were only shown when the interactions of the A ring of the analog changed 
significantly.  
In summary, analogs B2, C2, B4, B8, A13, A14, C17, B18, C18, A19, B19, A20, A21, 
A23, B30, A31, A32, B33 and C33 are the most promising in terms of adopted 
conformation, interactions with the VDR and score. Therefore, they are good 
candidates for synthesis and biological assays (Fig. 16).  
 
Fig. 16. Conformation of the most promising docked analogs 
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Fig. 16. Conformation of the most promising docked analogs (continuation) 
The different conditions tested also provided some interesting information, which is 
explored next.  
1.4.1. Docking results  of analogs depending on the carborane isomers 
Regarding the distinct conditions tested, it is possible to conclude that, overall, analogs 
with meta-carboranes appear to fit better in the binding pocket of VDR, as the 
connected R groups impart a favorable orientation. On the contrary,  
para-carborane containing analogs fit worse in the binding pocket, as most R groups 
do not interact with residues His305 and His397. This preference is detected in regards 
to both ligand poses, interaction with the VDR and docking scores.  
For example, when comparing analogs B3 (ortho-carborane), B19 (meta-carborane) 
and B35 (para-carborane, Table 1), it is possible to see that analog B19 fits better, has 
a better score and its R group forms more stable hydrogen bonds with the receptor.  
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Table 1. Comparison of docking scores for analogs containing different carborane isomers. First line shows a 
representation of the docked analog. Last line shows the docking result for each ligand superimposed with calcitriol 
inside the VDR binding pocket. Calcitriol is represented in grey. 
   
B3 (109%) B19 (117%) B35 (103%) 
   
 
From these docking results, it is possible to observe that the theoretical binding affinity 
for the VDR depends on the carborane isomer attached to the side chain.  Thus, these 
in silico results postulate that similar compounds containing distinct carborane isomers 
could have different biological properties. Therefore, we decided to synthesize  
ortho-, meta- and para-carborane analogs. 
1.4.2. Docking results  of analogs with different side chain sizes and R groups 
Regarding the size of the side chain, it was concluded that the preferred length of the 
side chain (n) greatly depends on the size of the R groups. Analogs with smaller R 
groups (-H or -OH) benefit from larger side chains (n=3), while analogs with 
intermediate to large R groups (alcohols, esters or hemiacetals) fit better inside the 
VDR when combined with smaller side chains (n=1 or n=2).  
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For example, with regard to small R groups (Table 2), analog C17 (n=3) has a better 
score than the other two analogs, A17 (n=1) and B17 (n=2), as it fits better inside the 
binding pocket.  
Table 2. Comparison of docking score for analogs with small R groups. First line shows a representation of the docked 
analog. Last line shows the docking result for each ligand superimposed with 
 calcitriol (grey) inside the VDR binding pocket.  
   
A17 (102%) B17 (113%) C17 (119%) 
   
 
Intermediate sized groups, such as small alcohols, are better in combination with an 
intermediate side chain length (Table 3). For example, analog B22 (n=2) has a better 
score than analogs A22 (n=1) and C22 (n=3), which contain smaller and larger side 
chains, respectively. Analog B22 is able to adopt a conformation similar to that of 
calcitriol, while forming similar hydrogen bonds with His305 and His397.  
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Table 3. Comparison of docking score for analogs with intermediate R groups. First line shows a representation of the 
docked analog. Last line shows the docking result for each ligand superimposed with calcitriol (grey) inside the VDR 
binding pocket 
   
A22 (105%) B22 (112%) C22 (111%) 
   
 
When it concerns larger R groups, such as large ketone, acetal and hemiacetal 
substituents, a smaller side chain (n=1) is often favourable (Table 4). In this case,  
analogs A32 (n=1) and B32 (n=2) have similar docking results. However, analog A32 
binds to both His305 and His397 and adopts a more preferable conformation inside the 
pocket. On the contrary, analog C32 is clearly too large to fit the binding pocket, as 
seen from its distorted side chain and CD bicycle.  
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Table 4. Comparison of docking score for analogs with large R groups. First line shows a representation of the docked 
analog. Last line shows the docking result for each ligand superimposed with calcitriol (grey) inside the VDR binding 
pocket 
   
A32 (104%) B32 (107%) C32 (98%) 
   
 
These results demonstrate that the choice of side chain size depends on the R group.  
1.5. Choice of target analogs for synthesis 
Compounds A1, A17 and A33 (Table 5) were investigated as possible targets to study 
the biological role of the ortho-, meta- and para-carboranes. Since they have a different 
side chain length (n=1) than the previously synthesized RO analog (n=3), these 
compounds would also be useful to study the effect of the side chain length in the 
analogs’ biological behavior.  
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Table 5. Target analogs for synthesis. . First line shows a representation of the docked analog. Last line shows the 
docking result for each ligand inside the VDR binding pocket 
 
   
 
  
A1 (98%) A17 (102%) A33 (97%) 
 
In addition, these analogs could be used as precursors of promising hemiacetal 
analogs. One of the long term goals of this research group is the synthesis of  
carborane-containing calcitriol analogs with stable hemiacetal substituents on the 
carborane, to test their stability and biological properties. From the hemiacetal analogs 
tested, compounds A13, A14, A31 and A32, which have ortho- or meta-carboranes 
and a side chain length of n=1, were the most promising (Fig. 16). Since analogs A1, 
A17 and A33 have the same side chain length and carborane isomers, they could be 
used as precursors to these hemiacetal compounds. 
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In terms of docking results, these analogs have docking scores similar to 1,25D. They 
adopt a favorable conformation inside the receptor and bind to the same amino acids 
as calcitriol. Therefore, they should have binding affinity towards the VDR and should induce 
transcription.                 .   
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2. CHAPTER II: Synthesis of Carborane Analogs A1, A17 and A33 
2.1. Retrosynthesis 
The retrosynthesis analysis for the preparation of the target compounds A1, A17 and 
A33 is depicted in Scheme 9. 
 
Scheme 9. Retrosynthetic analysis planned for the synthesis of compounds A1, A17 and A33. P = protecting group 
The key step of the synthesis is the introduction of the carborane moiety at the end of 
the synthesis by reaction of the corresponding carboranyllithium on tosylate 1.  
The triene system would be built by a stereoselective Pd-catalyzed ring closure on 
enol-triflate 3 and subsequent Suzuki-Miyaura coupling with alkenyl-boronic ester 2. 
The enol-triflate 3 would arise from epoxide 5, following procedures previously 
developed in this laboratory.53 The required boronic ester 2 would be prepared from  
Inhoffen-Lythgoe diol 4 by oxidation, Wittig chemistry and Pd-catalysed Br-B 
interchange.54  
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2.2. Synthesis of benzoate 6 
The synthesis started with known Inhoffen-Lythgoe diol (4), prepared from reductive 
ozonolysis of commercial vitamin D2,
55 which was converted to benzoate 6 (Scheme 
10).  
Diol 4 was treated with nBuLi, at low temperature, followed by addition of benzoyl 
chloride to give compounds 6 (14%), 7 (8%) and 8 (21%), together with starting 
material 4 (52%).  
 
Scheme 10. Synthesis of benzoate 6 by metalation of diol 4 
We next tried to improve the yield of the desired benzoate 6. Thus, treatment of diol 4 
with benzoyl chloride in the presence of 2,6-lutidine, in dichloromethane, provided 
benzoate 6 in a good yield (Scheme 11).  
 
Scheme 11. Selective synthesis of benzoate 6 
Fig. 17 shows the most significant 1H-NMR and 13C-NMR signals of benzoate 6  
 
Fig. 17. 
1
H-NMR and 
13
C-NMR main signals for compound 6 
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2.3. Synthesis of boronic ester 2 
Boronic ester 2 was then prepared in 50% overall yield, following  
previously developed procedures of this laboratory, which involve Dess-Martin 
oxidation, Wittig chemistry and Miyaura borylation (Scheme 12).56-57 
 
Scheme 12. Synthesis of boronic ester 2 
The oxidation of alcohol 6 with Dess-Martin periodinane in CH2Cl2 afforded ketone 9 in 
excellent yield.  
Wittig chemistry between ketone 9 and ylide Ph3P=CHBr, generated in situ by 
treatment of (bromomethyl)triphenylphosphonium bromide with potassium tert-butoxide 
in toluene, provided vinyl bromide 10 in a 74% yield.  
The alkenyl bromide 10 was then converted to boronate 2 in 68% yield by a Pd(0) 
catalyzed cross-coupling reaction employing bis(pinacolate)diboron and 
PdCl2(dppf)•CH2Cl2, as the catalyst, in the presence of tricyclohexylphosphine and 
KOAc in DMSO.57  
Scheme 13 depicts the proposed mechanism for this Miyaura borylation.  
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Scheme 13. Proposed mechanism for the Miyaura borylation reaction in the synthesis of boronic ester 2 
The reaction starts with the in situ formation of the Pd(0) catalyst, which is then 
inserted in the C-Br bond of the vinyl halide through oxidative addition. Then, 
transmetallation with bis(pinacolate)diboron, followed by reductive elimination, 
furnishes boronate 2 and leads to the regeneration of Pd(0).  
Fig. 18 shows the most significant 1H-NMR and 13C-NMR signals of boronic ester 2.  
 
Fig. 18. Main 
1
H-NMR and 
13
C-NMR signals for boronic ester 2 
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2.4. Synthesis of enol-triflate 3 
The enol-triflate 3 was prepared from the diprotected epoxide 5, following previously 
developed procedures (Scheme 14).58 
 
Scheme 14. Synthesis of enol triflate 3 
Epoxide 5 was converted to dibromide 12 by a two-step sequence. Periodic  
acid-oxidative cleavage of the epoxide 5 in Et2O gave aldehyde 11, which was 
transformed into dibromide 12 by Corey-Fuchs’ conditions.59  
Finally, the enol-triflate 3 was obtained in moderate yield from dibromide 12, by 
treatment with lithium diisopropylamide (LDA), followed by reaction of the resulting 
enolate with N-(5-chloro-2-pyridyl)triflimide (Comins’ reagent).  
Fig. 19 shows the most significant 1H-NMR and 13C-NMR signals of enol-triflate 3. 
 
Fig. 19. 
1
H-NMR and 
13
C-NMR signals of enol-triflate 3 
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2.5. Synthesis of tosylate 1 
With the upper and lower fragments in hand, we proceeded to build the vitamin D triene 
system by a Pd-catalyzed ring closure of enol-triflate 3, followed by Suzuki Miyaura 
cross-coupling with boronate 2, in the presence of aqueous K3PO4, to give 13 in 68% 
yield (Scheme 15). 
 
Scheme 15. Synthesis of benzoate 13 via carbociclization and Suzuki-Miyaura cross-coupling of 2 and 3 
 The proposed mechanism for this reaction is shown in Scheme 16.  
 
Scheme 16. Proposed mechanism of action of the Suzuki Miyaura cross-coupling to afford 13 
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The Pd(0) complex coordinates with the alkyne group of enol-triflate 3, which is 
followed by oxidative addition to the triflate group to furnish intermediate compound a. 
Then, a Pd-catalyzed Heck-type addition produces the Pd(II) intermediate (b), which 
undergoes a transposition with an activated boronate to produce intermediate c. 
Finally, this intermediate is transformed into benzoate 13 by reductive elimination, 
which is accompanied by the regeneration of the Pd(0) complex.  
To facilitate the introduction of the carborane moiety in the side chain, tosylate 1, which 
contains a good leaving group at C-22, was prepared from benzoate 13 in a two-step 
sequence (71% yield, Scheme 17). 
 
Scheme 17. Synthesis of tosylate 1 
Ester 13 was reduced with DIBAL-H to alcohol 14, which upon tosylation afforded the 
desired compound 1 in good yield.  
Fig. 20 shows the most significant 1H-NMR and 13C-NMR signals of tosylate 1.  
 
Fig. 20. Main 
1
H-NMR and 
13
C-NMR signals of tosylate 1 
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2.6. Synthesis of analogs A1, A17 and A33 
As mentioned in the introduction, the carborane unit was previously introduced in the 
side chain of a vitamin D analog via reaction of an alkyne with decaborane (B10H14), in 
the presence of N,N-dimethylaniline.49 However, this methodology had some 
drawbacks, including low reaction yields and high toxicity of decaborane. Additionally, 
this reaction only allows the production of ortho-substituted derivatives. Since one of 
the purposes of this work is the synthesis of analogs with ortho, meta and  
para-carborane units at the side chain, we focused on an alternative method to directly 
introduce the carborane moiety. A SN2 reaction between tosylate 1 and a 
carboranyllithium was found suitable for this purpose.  
Thus, direct displacement of the tosylate group of 1 with ortho-carboranyllithium, 
generated by reaction of the ortho-carborane with nBuLi, provided the ortho-carborane 
derivative 15, which was deprotected with aqueous HF to furnish the desired vitamin D 
analog A1 in good yield (54%, 2 steps, Scheme 18).  
 
 
Scheme 18. Synthesis of analog A1 
The ortho-carborane analog A1 was obtained from the Inhoffen-Lythgoe in 9 steps and 
12% overall yield. 
Fig. 21 shows the 1H-NMR spectrum of vitamin D analog A1.  
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Fig. 21. 
1
H-NMR spectrum of analog A1 
The well-defined singlet at 3.53 ppm corresponds to the C-24 proton of the  
ortho-carborane unit. The 10 H of the carborane moiety, present at the 10 BH vertices, 
appear as a wide band between 3.0-1.0 ppm, as seen by the increase of the baseline 
of the spectrum. 
The 11B-NMR spectrum of analog A1 (Fig. 22) shows that the 10 BH protons of the 
carborane unit are divided in 5 signals that integrate in the ratio 1:1:2:4:2 (-2.3, -5.6,  
-9.3, -11.6 and -13.1 ppm). This spectrum is similar to the known spectrum of free 
ortho-carborane, which confirms the successful introduction of this moiety in the target 
analog.46, 60  
 
Fig. 22. 
11
B-NMR spectrum of analog A1 
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Following the same methodology, analog A17 was synthesized from tosylate 1 in a 
60% yield (2 steps, Scheme 19).   
 
Scheme 19. Synthesis of analog A17 
The meta-carborane analog A17 was obtained from the Inhoffen-Lythgoe in 9 steps 
and 13% overall yield. 
Fig. 23 shows the 1H-NMR spectrum of vitamin D analog A17  
 
 
 
 
 
Fig. 23. 
1
H-NMR spectrum of analog A17 
 
The well-defined singlet at 2.90 ppm corresponds to the proton of C-24. The wide band 
between 3.00 and 1.00 ppm, observed by the increase of the baseline of the spectrum, 
corresponds to the 10 BH protons.  
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The 11B-NMR spectrum of analog A17 (Fig. 24) shows that the 10 BH protons of the  
meta-carborane unit of the analog A17 are divided in 4 different sets in the ratio 2:4:2:2 
(-3.8, -10.7, -13.7, -15.1 ppm), which is similar to the spectrum obtained for the free 
meta-carborane.46  
 
Fig. 24. 
11
B-NMR spectrum of analog A17 
Following the same methodology, analog A33 was prepared from tosylate 1 in a 48% 
yield (2 steps, Scheme 20).  
 
Scheme 20. Synthesis of analog A33 
The synthesis of A33 was accomplished in 9 steps and a 12% overall yield from the 
Inhoffen-Lythgoe diol.  
Fig. 25 shows the 1H-NMR spectrum of vitamin D analog A33.  
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Fig. 25. 
1
H-NMR spectrum of analog A33 
The proton of C-24 of the para-carborane moiety appears as a singlet at 2.59 ppm. The 
10 H of the BH units appear as a wide band between 3.0-1.0 ppm, similarly to the other 
analogs.  
The decoupled 11B-NMR spectrum of analog A33 (Fig. 26) shows that the 10 BH 
protons of the para-carborane unit of the analog A33 are divided in 2 different sets in 
the ratio 5:5 (-12.3; -15.2 ppm). One of the signals is assigned to the 5 boron atoms 
closer to the free CH group and the other signal is assigned to the BH vertices closer to 
C-23.  
 
Fig. 26. 
11
B-NMR spectrum of analog A33 
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The biological properties of these compounds could not be evaluated in time to be 
included in this work, but the analogs are currently taking part in different biological 
tests (competitive binding assays, ability to induce transcription activity, cellular 
proliferation and differentiation in several cell lines and the capacity to modulate 
calcium serum levels in mice).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSIONS  
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Conclusions 
Docking calculations of 144 carborane-containing vitamin D analogs into the binding 
pocket of human vitamin D receptor [hVDR(LBD)] were accomplished. Several 
analogs, namely B2, C2, B4, B8, A13, A14, C17, B18, C18, A19, B19, A20, A21, A23, 
B30, A31, A32, B33 and C33, bind to hVDR(LBD) better than 1α,25-dihydroxyvitamin 
D3 (1,25D). Therefore, they are good candidates for synthesis and biological testing. 
Analogs A1, A17 and A33 were synthesized to investigate whether the ortho, meta and 
para-carborane unit and the side chain size could impart different biological properties, 
and based on docking calculations.  
These secosteroid analogs (A1, A17 and A33), bearing an ortho, meta and  
para-carborane at the side chain, respectively, were synthesized from the  
Inhoffen-Lythgoe diol, in a total of 9 steps and about 12% overall yield.  The key step 
was the introduction of the carborane unit at the end of the synthesis by SN2 
displacement of a tosylate group by a carboranyllithium, which proved to be an 
improvement on the published synthetic approach. 
This work allowed the establishment of a good synthetic methodology for the synthesis 
of vitamin D analogs with ortho, meta and para carboranes attached at the side chain.  
Future endeavors include the in vitro and in vivo biological testing of the synthesized 
compounds, as well as the synthesis of new promising carborane-containing analogs, 
following the synthetic approach developed in this work. 
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Experimental Section  
1. Docking Calculations 
The receptor and the ligands were used as MOL2 files. Energy minimization was not 
performed on the protein. The ligands were built using the PyMol program,50 by 
modification of the crystal structure of 1,25D. The vitamin D part was obtained from the 
crystal structure of the complex of 1,25D-hVDR LBD (PDB code: 1DB1).11 The 
carborane cage part of the ligands was obtained from the crystal structure of the 
corresponding ortho (PDB code: 5E7V)49, meta (PDB code: 4MDL)51 and  
para-carboranes (PDB codes: 3VJS).52 The ligands were further treated by adding 
hydrogen atoms and checking atom valence using Chem3D. Energy minimization of 
the ligands was performed using the MM2 function of Chem3D. The boron atoms “B” 
were considered as carbon sp3 atoms only for the empirical potential energy function. 
Docking studies to predict the affinity of the new ligands for the VDR were carried out 
using the GOLD program (version Suite 5.2). A modified crystal structure (addition of 
hydrogen, reconstituted gaps and corrected His tautomers) of the complex between 
1,25D-hVDR LBD was chosen as protein (PBD code: 1DB1).11  
The Ligand Binding Pocket of the mutant LBD was defined as Binding Site with the 
automatic active-site detection on, and the radius was set to 10 Å. Ligand was docked 
in 25 independent genetic algorithm (GA) runs, for each of which a maximum of 
125000 GA operations were performed on a single population of 100 individuals. 
Operator weights for crossover, mutation, and migration in the entry box were used as 
default parameters (95, 95, and 10, respectively), as well as the hydrogen bonding  
(4.0 Å) and van der Waals (2.5 Å) parameters. The “flip ring corners” flag was switched 
off, while all the other flags were on. CHEMPLP was used as a scoring function and 
GoldScore as a re-scoring function. The best 3 solutions were obtained with an 
associated score. These results were compared with the solutions for 1,25D.  
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2. General Procedures  
All reactions involving oxygen- or moisture-sensitive compounds were carried out 
under a dry Ar atmosphere using oven-dried or flame-dried glassware and standard 
syringe/septa techniques, unless when indicated. Liquid reagents or solutions of 
reagents were added by syringe or cannula techniques. Reaction temperatures refer to 
external bath temperatures. Reactions at low temperatures were performed in 
methanol baths cooled with a CRYOCOOL immersion cooler CC-90 (EK-90 de Thermo 
Fisher Scientific), provided with a temperature regulator. Reactions at high 
temperatures were carried out using silicon baths, with a temperature regulator. All dry 
solvents were distilled under Ar immediately prior to use. Tetrahydrofuran (THF), Et2O 
and toluene were distilled from Na/benzophenone. Pyridine and 2,6-Lutidine were 
distilled from CaH2. CH2Cl2 was distilled from P2O5. DMSO was distilled from CaH2 at 
low pressure and kept over 4 Å molecular sieves. tert-Butyl methyl ether (MTBE) and 
CH2Cl2 for extractions was used as received. Solutions of 
nBuLi in hexanes were 
titrated with N-benzylbenzamide before use. The organic extracts were dried over 
anhydrous Na2SO4, filtered and concentrated using a rotary evaporator at aspirator 
pressure (20-30 mmHg). Reactions were monitored by thin-layer chromatography 
(TLC) using aluminum-backed MERCK 60 silica gel plates (0.2 mm thickness). The 
chromatograms were visualized first with ultraviolet light (254 nm) and then by 
immersion in solutions of ceric ammonium molybdate or p-anisaldehyde followed by 
heating with a heater gun. Flash column chromatography was performed with Merck 
silica gel 60 (230-400 mesh). All NMR spectra were measured with solutions in CDCl3 
in a Bruker DPX-250 (250 MHz), Varian Inova 400 (400 MHz) or Bruker DRX-500 (500 
MHz) spectrometers. Chemical shifts are reported on the δ scale (ppm) downfield from 
tetramethylsilane (δ = 0.0 ppm) using the residual solvent signal at δ = 7.26 ppm (1H, s, 
CDCl3) or δ = 77.0 ppm (
13C, t, CDCl3). Coupling constants (J) are reported in Hz. 
Distortionless Enhancement by Polarization Transfer (DEPT-135) was used to assign 
carbon types. NMR signals have been assigned using steroidal numbering. High 
resolution mass spectra (HRMS) were performed in a Micromass Instruments 
Autospec, Thermo Finningan MAT95XP and Applied Biosystems QSTAR Elite 
spectrometers. IR spectra were recorded on a silicon disc on a Bruker IFS-66V and 
VECTOR 22 FT-IR spectrometers. Optical rotations were measured on a Jasco DIP-
370 polarimeter in a 1 dm cell. [α] and c are given in cm3.g-1.dm-1 and g.cm-3, 
respectively. HPLC purifications were performed on a Shimadzu preparative liquid 
chromatograph model LC-8A equipped with a TSP UV-1 absorbance detector, using 
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HPLC Phenomenex Luna 5u Silica column (SiO2, 5 µ, 100A, Ø 250 mm x 21.2 mm). 
Yields refer to chromatographically purified compounds, unless otherwise stated. 
The reference and distributor for each reactant used in this work is listed below: 
2,6-Lutidine, Acros, EW-88124-07 HF, 48-51%, Acros, Ref.223335000 
B2Pin2, Aldrich, Ref. 47,329-4 KOAc, Merck, Ref. 104820 
nBuLi, Acros, 18127 KOtBu, Fluka, Ref. 60100  
K3PO4·3H2O, Aldrich, Ref. P5629 m-Carborane, Katchem, Ref. 200 
BzCl, Aldrich, 259950 o-Carborane, Katchem, Ref. 199 
CBr4, Aldrich, Ref. C11081 p-Carborane, Katchem, Ref.201 
DIBAL-H, Aldrich, Ref. 214973 PCy3, Aldrich, Ref. 261971 
DMAP, Fluka, Ref. 29224 PdCl2(dppf)·CH2Cl2, Aldrich, Ref. 379670 
H5IO6, Fluka, Ref. 77310 PdCl2(PPh3)2, Fluka, Ref. 15253 
HF, Acros, Ref.423805000 PPh3, Aldrich, Ref. T84409 
DMP, Carbolution, Ref.CC03024 TsCl, Aldrich, Ref. T35955 
 Zn, Strem, Ref. 933056 
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(S)-2-[(1R,3aR,4S,7aR)-4-hydroxy-7a-methyloctahydro-1H-inden-1-yl}propyl 
benzoate (6) 
 
Benzoyl chloride (1.3 mL, 11.3 mmol, 2 equiv) was added dropwise to a 0 ºC cooled 
solution of diol 4 (1.2 g, 5.6 mmol, 1 equiv) and 2,6-lutidine (2.0 mL, 17.0 mmol,  
3 equiv) in CH2Cl2 (20 mL). The reaction mixture was stirred for 5 h and then quenched 
by the addition of aqueous HCl (5%, 10 mL). The mixture was extracted with MTBE 
(3x10 mL) and the combined organic layers were dried, filtered and concentrated. The 
residue was purified by flash chromatography (SiO2, Ø 2.5x5 cm,  
0-20% EtOAc/hexanes) to afford 6 [1.6 g, 5.1 mmol, 90%, yellowish oil; Rf = 0.69 (30% 
EtOAc/hexanes), [𝛼]𝐷
25 = + 30.2 (c 1.12, CHCl3)].  
1H NMR (250 MHz, CDCl3): δ 8.04 (d, J = 7.4 Hz, 2H, Har), 7.55 (dd, J = 8.2 and  
6.4 Hz, 1H, Har), 7.44 (t, J = 7.6 Hz, 2H, Har), 4.31 (dd, J = 10.7 and 3.4 Hz, 1H,  
H-22), 4.06 (dd, J = 10.7 and 7.1 Hz, 2H, H-8 and H-22), 2.04 – 1.20 (m, 14H), 1.10 (d, 
J = 6.6 Hz, 3H, CH3-21), 0.99 (s, 3H, CH3-18). 
13C NMR (63 MHz, CDCl3): δ 166.9 (C, 
C=O), 132.9 (CH, CHar), 130.7 (C, Car), 129.6 (CH, 2xCHar), 128.5 (CH, 2xCHar),  
70.0 (CH2, C-22), 69.3 (CH, C-8), 53.5 (CH), 52.5 (CH), 42.1 (C, C-13), 40.4 (CH2), 
35.7 (CH), 33.7 (CH2), 26.9 (CH2), 22.71 (CH2), 17.54 (CH2), 17.38 (CH3, CH3-21), 
13.71 (CH3, CH3-18). IR (film, cm
-1): 3533 (νO-H), 2941(νC-H),  2871 (νC-H), 1718 
(νC=Oester). HRMS ([ESI-TOF]
+, m/z) [M+H]+ calcd for C20H29O3, 317.2111; found 317.2110. 
 
(S)-2-[(1R,3aR,7aR)-7a-methyl-4-oxooctahydro-1H-inden-1-yl]propyl benzoate (9) 
 
Dess–Martin periodinane (DMP, 2.4 g, 5.8 mmol, 1.1 equiv) was added to a solution of 
6 (1.6 mg, 5.1 mmol, 1 equiv) in CH2Cl2 (40 mL). The reaction mixture was stirred at rt 
for 1.5 h and then concentrated. The residue was purified by flash chromatography 
(SiO2, Ø 3x6 cm, 30% EtOAc/hexanes) to give ketone 9 [1.5 g, 4.9 mmol, 97%, 
colorless oil; Rf = 0.70 (20% EtOAc/hexanes), [𝛼]𝐷
25 = + 0.67 (c 0.92, CHCl3)].  
1H NMR (250 MHz, CDCl3): δ 8.04 – 7.96 (m, 2H, Har), 7.57 – 7.48 (m, 1H, Har), 7.41 (t, 
J = 7.4 Hz, 2H, Har), 4.29 (dd, J = 10.8 and 3.4 Hz, 1H, H-22), 4.05 (dd,  
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J = 10.8 and 6.8 Hz, 1H, H-22), 2.45 (dd, J = 11.4 and 7.5 Hz, 1H), 2.24 – 1.39 (m, 
12H), 1.12 (d, J = 6.6 Hz, 3H, CH3-21), 0.65 (s, 3H, CH3-18). 
13C NMR (63 MHz, 
CDCl3): δ 211.7 (C, C=O, C-8), 166.6 (C, C=O), 132.9 (CH, CHar), 130.4 (C, Car), 129.5 
(CH, 2xCHar), 128.4 (CH, 2xCHar), 69.6 (CH2, C-22), 61.6 (CH), 53.4 (CH), 49.9 (C,  
C-13), 40.9 (CH2), 38.8 (CH2), 35.8 (CH), 27.0 (CH2), 24.0 (CH2), 19.2 (CH2),  
17.4 (CH3, CH3-21), 12.5 (CH3, CH3-18). IR (film, cm
-1): 2962 (νC-H), 2873 (νC-H), 1714 
(νC=Oester), 1601 (νC=Oketone). HRMS ([ESI-TOF]
+, m/z) [M+H]+ calcd for C20H27O3, 
315.1955; found 315.1956. 
(S)-2-[(1R,3aR,7aR,E)-4-(bromomethylene)-7a-methyloctahydro-1H-inden-1-
yl]propyl benzoate (10) 
 
A suspension of (bromomethylene)triphenylphosphonium bromide (2.0 g, 4.5 mmol,  
5 equiv) in toluene (18 mL) was sonicated for 30 min and then cooled to -15 ºC. After 
10 min, a solution of KOtBu in THF (4.5 mL, 4.5 mmol, 1M, 4.9 equiv) was added 
dropwise. The yellow mixture was stirred at -15 ºC for 1.5 h and at 0 ºC for 30 min. The 
ylide was cooled to -15 ºC. A 0 ºC cooled solution of ketone 9 (286 mg,  
0.910 mmol, 1 equiv) in toluene (9 mL) was added dropwise via canula. The mixture 
was stirred at -15 ºC for 1.5 h. The reaction was quenched by addition of sat NH4Cl  
(5 mL). The mixture was filtered through a short pad of silica gel, rinsed with EtOAc 
and concentrated. The residue was purified by flash chromatography (SiO2, Ø 2×6 cm,  
0-3% EtOAc/hexanes) to give bromide 10 [262 mg, 0.670 mmol, 74%, Rf = 0.71  
(20% EtOAc/hexanes), colorless oil, [𝛼]𝐷
25 = + 85.0 (c 1.1, CHCl3)]. 
1H NMR (250 MHz, CDCl3): δ 8.10 – 8.00 (m, 2H, Har), 7.57 (t, J = 7.3 Hz, 1H, Har), 
7.45 (t, J = 7.6 Hz, 2H, Har), 5.67 (s, 1H, H-7), 4.33 (dd, J = 10.8 and 3.3 Hz, 1H, H-22), 
4.08 (dd, J = 10.7 and 7.0 Hz, 1H, H-22), 2.90 (dd, J = 10.2 and 2.8 Hz, 1H),  
2.08 – 1.24 (m, 12H), 1.14 (d, J = 6.6 Hz, 3H, CH3-21), 0.62 (s, 3H, CH3-18). 
13C NMR  
(63 MHz, CDCl3): δ 166.8 (C, C=O), 144.9 (C, C-8), 133.0 (CH, CHar), 130.6 (C, Car), 
129.7  (CH, 2xCHar), 128.5 (CH, 2xCHar), 97.8 (CH, C-7), 69.9 (CH2, C-22), 55.7 (CH), 
52.7 (CH), 45.8 (C, C-13), 39.9 (CH2), 36.4 (CH), 31.1 (CH2), 27.3 (CH2), 22.6 (CH2), 
22.3 (CH2), 17.6 (CH3, CH3-21), 12.1 (CH3, CH3-18). IR (film, cm
-1): 2947 (νC-H), 2870 
(νC-H), 1718 (νC=O). HRMS ([ESI-TOF]
+, m/z) [M+H]+ calcd for C21H28BrO2, 319.1254; 
found 319.1264. 
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(S)-2-{(1R,3aS,7aR,E)-7a-methyl-4-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)methylene]octahydro-1H-inden-1-yl}propyl benzoate (2) 
 
 
 
Tricyclohexylphosphine (PCy3, 10.7 mg, 0.038 mmol, 0.06 equiv) and 
PdCl2(dppf)•CH2Cl2 (15.7 mg, 0.019 mmol, 0.03 equiv) were dissolved in dry DMSO  
(2 mL). The mixture was stirred at rt for 20 min. A solution of 10 (250 mg, 0.639 mmol,  
1 equiv) in DMSO (5 mL) was added via canula. B2pin2 (324 mg, 1.28 mmol, 2 equiv) 
and KOAc (251 mg, 2.55 mmol, 4 equiv) were successively added. The reaction 
mixture was stirred at 80 ºC for 2 h, cooled to rt and then diluted with H2O (10 mL). The 
mixture was extracted with MTBE (3x10 mL) and the combined organic layers were 
dried, filtered and concentrated. The residue was purified by flash chromatography 
(SiO2, Ø 1.5x6 cm, hexanes) to give 2 [191 mg, 0.44 mmol, 68%, Rf = 0.58  
(10% EtOAc/hexanes), yellowish wax, [𝛼]𝐷
25 = + 62.4 (c 1.0, CHCl3)]. 
1H NMR (250 MHz, CDCl3): δ 8.04 (d, J = 7.0 Hz, 2H, Har), 7.61 – 7.50 (m, 1H, Har), 
7.44 (t, J = 7.2 Hz, 2H, Har), 4.93 (s, 1H, H-7), 4.32 (dd, J = 9.9 and 2.0 Hz, 1H, H-22), 
4.06 (dd, J = 10.4 and 7.0 Hz, 1H, H-22), 3.19 (d, J = 12.8 Hz, 1H,  
H-14), 2.12 – 1.37 (m, 12H), 1.26 (s, 12H, 4xCH3COB), 1.12 (d, J = 6.4 Hz, 3H,  
CH3-21), 0.60 (s, 3H, CH3-18). 
13C NMR (63 MHz, CDCl3): δ 166.9 (C, C-8),  
165.8 (C=O, Car), 132.9 (CH, CHar), 130.6 (C, Car), 129.6 (CH, 2xCHar), 128.5 (CH, 
2xCHar), 82.7 (C, 2xCH3COB), 70.0 (CH2, C-22), 57.8 (CH, C-7), 53.6 (CH), 46.4 (C,  
C-13), 40.4 (CH2), 36.4 (CH, C-20), 33.3 (CH2), 27.1 (CH2), 25.0 (CH3, 2xCH3COB), 
24.9 (CH3, 2xCH3COB), 24.4 (CH2), 22.5 (CH2), 17.6(CH3, CH3-21), 12.3 (CH3,  
CH3-18).IR (film, cm
-1): 2980 (νC-H), 2870 (νC-H), 1780 (νC=O), 1639 (νC=C). HRMS  
([ESI-TOF]+, m/z) [M+H]+ calcd for C27H40BO4, 439.3014; found 439.3020. 
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(S)-2-{(1R,3aS,7aR,E)-4-[(Z)-2-8((3S,5R)-3,5-bis((tert-butyldimethylsilyl)oxy)-2-
methylenecyclohexylidene)ethylidene]-7a-methyloctahydro-1H-inden-1-yl}propyl 
benzoate (13) 
 
An aqueous solution of K3PO4 (5 mL, 2M, 15 equiv) was added to a solution of 
boronate 2 (300 mg, 0.684 mmol, 1 equiv) and enol-triflate 3 (424 mg, 0.821 mmol,  
1.2 equiv) in THF (5 mL). Then, PdCl2(PPh3)2•CH2Cl2 (24 mg, 0.034 mmol, 0.05 equiv) 
was added. The reaction mixture was vigorously stirred for 1.5 h, in the dark. The 
reaction was quenched by addition of H2O (10 mL). The mixture was extracted with 
MTBE (3x10 mL) and the combined organic layers were dried, filtered and 
concentrated. The residue was purified by flash chromatography (SiO2, Ø 2,5x6 cm, 
hexanes) to give 13 [300 mg, 0.440 mmol, 68%, Rf = 0.77 (5% EtOAc/hexanes), white 
foam, [𝛼]𝐷
25 = + 2.2 (c 0.48, CHCl3)]. 
1H NMR (250 MHz, CDCl3): δ 8.06 (d, J = 8.0 Hz, 2H, Har), 7.57 (t, J = 6.9 Hz, 1H, Har), 
7.45 (t, J = 7.7 Hz, 2H, Har), 6.25 (d, J = 11.4 Hz, 1H, H-6), 6.04 (d,  
J = 11.1 Hz, 1H, H-7), 5.22 – 5.14 (s, 1H, H-19), 4.87 (s, J = 2.2 Hz, 1H, H-19),  
4.41 – 4.29 (m, 2H, H-22), 4.25 – 4.14 (m, 1H, H-1), 4.10 – 4.02 (m, 1H, H-3),  
2.90 – 2.78 (m, 1H, H-9), 2.46 (dd, J = 13.1 and 3.3 Hz, 1H, H-4), 2.22 (dd,  
J = 13.1 and 7.2 Hz, 1H, H-4), 1.92 – 1.45 (m, 14H), 1.14 (d, J = 6.4 Hz, 3H, CH3-21), 
0.90 – 0.81 (m, 18H, 2xCH3CSi), 0.59 (s, 3H, CH3-18), 0.11 – 0.00 (m, 12H, 4xCH3Si). 
13C NMR (63 MHz, CDCl3): δ 166.9 (C=O, Car), 148.4 (C, C-10), 140.7 (C, C-8),  
135.4 (C, C-5), 133.0 (CH, CHar), 130.7 (C, Car), 129.7 (CH, 2xCHar), 128.5 (CH, 
2xCHar), 123.2 (=CH, C-6), 118.2 (=CH, C-7), 111.4 (CH2, C-19), 72.2 (CH, C-1),  
70.1 (CH2, C-22), 67.7 (CH, C-3), 56.2 (CH), 53.4 (CH), 46.2 (CH2), 46.0 (C, C-13), 
44.9 (CH2), 40.6 (CH2), 36.5 (CH), 29.0 (CH2), 27.4 (CH2), 26.0 (CH3, 3xCH3CSi),  
25.96 (CH3, 3xCH3CSi), 23.6 (CH2), 22.4 (CH2), 18.4 (C, CH3CSi), 18.3 (C, CH3CSi), 
17.7 (CH3, CH3-21), 12.2 (CH3, CH3-18), -4.5 (CH3, 2xCH3Si), -4.6 (CH3, CH3Si),  
-4.9 (CH3, CH3Si). IR (film, cm
-1): 2918 (νC-H), 2849 (νC-H), 1724 (νC=O).  
HRMS ([APCI-TOF]+, m/z) [M+H]+ calcd for C41H67O4Si2, 679.4572; found 679.4574. 
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(S)-2-{(1R,3aS,7aR,E)-4-[(Z)-2-((3S,5R)-3,5-bis((tert-butyldimethylsilyl)oxy)-2-
methylenecyclohexylidene)ethylidene]-7a-methyloctahydro-1H-inden-1-
yl}propan-1-ol (14) 
 
 
A solution of DIBAL-H (1.5 mL, 1M, 3 equiv) was added dropwise to a -78 ºC cooled 
solution of 13 (300 mg, 0.442 mmol, 1 equiv) in CH2Cl2 (10 mL). The reaction mixture 
was stirred in dark for 1 h and then allowed to reach rt. The reaction was quenched by 
addition of H2O (20 mL) and aqueous HCl (10 mL, 5%). The mixture was stirred for  
15 min and then extracted with CH2Cl2 (3x10 mL). The combined organic layers were 
dried, filtered and concentrated. The residue was purified by flash chromatography 
(SiO2, Ø 2x6 cm, hexanes) to give 14 [247 mg, 0.430 mmol, 97%, yellow foam,  
Rf = 0.14 (5% EtOAc/hexanes),[𝛼]𝐷
25 = + 42.8 (c 0.60, CHCl3)]. 
1H NMR (250 MHz, CDCl3): δ 6.24 (d, J = 11.3 Hz, 1H, H-6), 6.02 (d,  
J = 11.2 Hz, 1H, H-7), 5.18 (s, 1H, H-19), 4.86 (s, 1H, H-19), 4.37 (dd, J = 6.3 and  
3.8 Hz, 1H, H-1), 4.19 (ddd, J = 10.8, 7.2 and 3.8 Hz, 1H, H-3), 3.65 (dd,  
J = 10.5 and 3.0 Hz, 1H, H-22), 3.38 (dd, J = 10.5 and 6.7 Hz, 1H, H-22),  
2.87 – 2.77 (m, 1H, H-9), 2.44 (dd, J = 13.0 and 3.3 Hz, 1H), 2.21 (dd,  
J = 13.0 and 7.1 Hz, 1H, H-4), 2.03 – 1.24 (m, 15H), 1.05 (d, J = 6.5 Hz, 3H, CH3-21), 
0.88 (s, 18H, 2x CH3CSi), 0.55 (s, 3H, CH3-18), 0.06 (s, 12H, 4x CH3Si).
 13C NMR  
(63 MHz, CDCl3): δ 148.5 (C, C-10), 140.9 (C, C-8), 135.3 (C, C-5), 123.2 (=CH, C-6), 
118.1 (=CH, C-7), 111.3 (=CH2, C-19), 72.2 (CH, C-1), 68.1 (CH2, C-22), 67. 7 (CH,  
C-3), 56.2 (CH), 52.9 (CH), 46.2 (CH2), 46.0 (C, C-13), 44.9 (CH2), 40.6 (CH2),  
39.24 (CH), 29.0 (CH2), 27.4 (CH2), 26.00 (CH3, 3xCH3CSi), 25.96 (CH3, 3xCH3CSi), 
23.6 (CH2), 22.4 (CH2), 18.4 (C, CH3CSi), 18.3 (C, CH3CSi), 17.0 (CH3, CH3-21),  
12.2 (CH3, CH3-18), -4.5 (CH3, 2xCH3Si), -4.6 (CH3, CH3Si),  -4.9 (CH3, CH3Si).  
HRMS ([ESI-TOF]+, m/z) [M+H]+ calcd for C34H63O3Si2, 575.4310; found 575.4309. 
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(S)-2-{(1R,3aS,7aR,E)-4-[(Z)-2-((3S,5R)-3,5-bis((tert-butyldimethylsilyl)oxy)-2-
methylenecyclohexylidene)ethylidene]-7a-methyloctahydro-1H-inden-1-yl}propyl 
4-methylbenzenesulfonate (1) 
 
p-Toluenesulfonyl chloride (120 mg, 0.629 mmol, 2.4 equiv) was added to a 0 ºC 
cooled solution of 14 (154 mg, 0.268 mmol, 1 equiv) in pyridine. The bright yellow 
reaction mixture was stirred overnight at -4 ºC, in dark. The reaction was quenched by 
addition of sat CuSO4 (20 mL). The mixture was extracted with MTBE (3x10 mL). The 
combined organic phases were dried, filtered and concentrated. The residue was 
purified by flash chromatography (SiO2, Ø 2x6 cm, hexanes) to give  
1 [143 mg, 0.196 mmol, 73%, colorless foam, Rf = 0.72 (20% EtOAc/hexanes), 
 [𝛼]𝐷
25 = + 3.2 (c 0.20, CHCl3)]. 
1H NMR (250 MHz, CDCl3): δ 7.79 (d, J = 8.3 Hz, 2H, Har), 7.34 (d, J = 8.4 Hz, 2H, Har), 
6.22 (d, J = 11.3 Hz, 1H, H-6), 5.99 (d, J = 11.6 Hz, 1H, H-7),  
5.17 (s, 1H, H-19), 4.84 (s, 1H, H-19), 4.36 (dd, J = 6.5 and 4.1 Hz, 1H, H-1),  
4.24 – 4.12 (m, 1H, H-3), 3.97 (dd, J = 9.2 and 2.9 Hz, 1H, H-22), 3.79 (dd,  
J = 9.2 and 6.3 Hz, 1H, H-22), 2.85 – 2.75 (m, 1H), 2.51 – 2.39 (m, 3H), 2.20 (dd,  
J = 13.2 and 6.9 Hz, 2H), 2.03 – 1.06 (m, 17H), 1.01 – 0.79 (m, 18H, 2xCH3CSi),  
0.49 (s, 3H, CH3-18), 0.05 (s, 12H, 4xCH3Si). 
13C NMR (63 MHz, CDCl3): δ 148.5 (C, 
C-10), 144.7 (C, Car), 140.4 (C, C-8), 135.5 (C, C-5), 133.2 (C, Car), 129.9 (2xCH, Car), 
128.1 (2xCH, Car), 123.1 (=CH, C-6), 118.3 (=CH, C-7), 111.3 (=CH2, C-19), 75.7 (CH2, 
C-22), 72.2 (CH, C-1), 67.6 (CH, C-3), 56.0 (CH), 52.3 (CH), 46.1 (C, C-13),  
45.9 (CH2), 44.9 (CH2, C-2), 40.4 (CH2, C-12), 36.7 (CH), 28.9 (CH2), 27.1 (CH2),  
25.99 (CH3, 3xCH3CSi), 25.96 (CH3, 3xCH3CSi), 23.5 (CH2), 22.2 (CH2), 21.8 (CH3, 
CH3-Ts), 18.37 (C, CH3CSi), 18.30 (C, CH3CSi), 17.1 (CH3, CH3-21), 12.1 (CH3,  
CH3-18), -4.5 (CH3, 2xCH3Si), -4.6 (CH3, CH3Si), -4.9 (CH3, CH3Si).  
HRMS ([APCI-TOF]+, m/z) [M+H]+ calcd for C41H69O5SSi2, 729.4399; found 729.4399. 
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1-{[(R)-2-((1R,3aS,7aR,E)-4-((Z)-2-((3S,5R)-3,5-dihydroxy-2-
methylenecyclohexylidene)ethylidene]-7a-methyloctahydro-1H-inden-1-
yl)propyl)} -1,2-dicarba-closo-dodecaborane (A1) 
 
A solution of nBuLi (78 µL, 2.5 M, 2 equiv) was added dropwise to a 0 ºC cooled 
solution of o-carborane (28 mg, 0.20 mmol, 2 equiv) in Et2O (2.5 mL). The bath was 
removed and the cloudy mixture was stirred at rt for 1 h. The reaction mixture was 
cooled to 0 ºC and, after 5 min, a solution of 1 (71 mg, 0.097 mmol, 1 equiv) in Et2O 
(1.5 mL) was added via canula. The yellow mixture was stirred in dark at 0 ºC for 2 h. 
Then, the bath was removed and the reaction mixture was stirred overnight at rt. The 
reaction was quenched by addition of H2O (10 mL) and extracted with MTBE  
(3x10 mL). The combined organic layers were dried, filtered and concentrated. The 
residue was purified by flash chromatography (SiO2, Ø 1,5x8 cm,  
1-5% EtOAc/hexanes) to give the protected analog 15 [45 mg, 0.064 mmol, 66%,  
Rf = 0.55 (10% EtOAc/hexanes)]. A solution of compound 15 (45 mg, 0.064 mmol,  
1 equiv) in CH2Cl2/CH3CN (4 mL, 1:3) was treated with aqueous HF (48%, 15 drops).  
The mixture was stirred at rt for 2 h and then poured into sat NaHCO3 (50 mL). The 
mixture was stirred for 30 min and then extracted with CH2Cl2 (3x20 mL). The 
combined organic layers were dried, filtered and concentrated. The residue was 
purified by flash chromatography (SiO2, Ø 1.5x7 cm, 60% EtOAc/hexanes) and then 
repurified by HPLC (Phenomenex SiO2, Luna Silica(2) 5 µm, 20% 
iPrOH/hexanes) to 
afford A1 [25 mg, 0.053 mmol, 82%, 54% 2 steps, white wax, Rf = 0.55  
(60% EtOAc/hexanes), [𝛼]𝐷
25 = + 6.7 (c 2.4, CHCl3)].  
1H NMR (400 MHz, CDCl3): δ 6.35 and 6.01 (d, J = 11.2 Hz, 2H, H-6 and H-7), 5.33 (s, 
1H, H-19), 4.99 (s, 1H, H-19), 4.43 (dd, J = 7.7 and 4.2 Hz, 1H, H-1),  
4.23 (dq, J = 9.5 and 3.3 Hz, 1H, H-3), 3.53 (s, 1H, H-24), 2.82 (dd, J = 12.2 and  
3.7 Hz, 1H), 2.59 (dd, J = 13.4 and 2.8 Hz, 1H), 2.36 – 2.28 (m, 3H), 2.07 – 1.78 (m, 
11H), 1.73 – 1.58 (m, 7H), 1.50 (dd, J = 18.9 and 9.8 Hz, 3H), 1.31 – 1.16 (m, 5H), 
1.04 (d, J = 6.3 Hz, 3H, CH3-21), 0.58 (s, 3H, CH3-18).
 13C NMR (63 MHz, CDCl3): δ 
147.8 (C, C-10), 142.3 (C, C-8), 133.6 (C, C-5), 124.9 (=CH, C-6),  
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117.6 (=CH, C-7), 111.9 (=CH2, C-19), 75.7 (C, C-23), 70.8 (CH, C-1), 67.0 (CH, C-3), 
62.2 (CH, C-24), 56.5 (CH), 56.2 (CH, 45.9 (C, C-13), 45.3 (CH2, C-4), 44.5 (CH2), 43.0 
(CH2), 40.4 (CH2), 37.7 (CH), 29.0 (CH2), 28.0 (CH2), 23.5 (CH2), 22.3 (CH2), 20.6 
(CH3, CH3-21), 12.1 (CH3, CH3-18). IR (film, cm
-1): 3361 (νO-H), 2955, 2918 (νC-H), 2849 
(νC-H), 2594 (νB-H), 1462. HRMS ([APCI-TOF]
+, m/z) [M]+ calcd for C24H44B10O2, 
474.4266; found 474.4304. 
 
1-{[(R)-2-((1R,3aS,7aR,E)-4-((Z)-2-((3S,5R)-3,5-dihydroxy-2-
methylenecyclohexylidene)ethylidene]-7a-methyloctahydro-1H-inden-1-
yl)propyl)} -1,7-dicarba-closo-dodecaborane (A17) 
 
A solution of nBuLi (104  µL, 2.5 M, 2 equiv) was added dropwise to a 0 ºC cooled 
solution of m-carborane (50 mg, 0.35 mmol, 2.6 equiv) in Et2O (3 mL). The bath was 
removed and the cloudy mixture was stirred at rt for 1 h. The reaction mixture was 
cooled to 0 ºC and, after 5 min, a solution of 1 (95 mg, 0.13 mmol, 1 equiv) in Et2O  
(2.5 mL) was added via canula. The yellow mixture was stirred in darkness for 30 min 
at 0 ºC. Then, the bath was removed and the reaction mixture was stirred overnight at 
rt. The reaction was quenched by addition of H2O (10 mL) and extracted with MTBE 
(3x10 mL). The combined organic layers were dried, filtered and concentrated. The 
residue was purified by flash chromatography (SiO2, Ø 1,5x5 cm,  
0-2% EtOAc/hexanes) to give the protected analog 16 [82 mg, 0.12 mmol, 90%,  
Rf = 0.88 (10% EtOAc/hexanes)]. A solution of compound 16 (82 mg, 0.12 mmol,  
1 equiv) in CH2Cl2/CH3CN (4 mL, 1:3) was treated with aqueous HF (48%, 15 drops).  
The reaction mixture was stirred at rt for 2 h and then poured into sat NaHCO3 (50 mL). 
The mixture was stirred for 30 min and then extracted with CH2Cl2 (3x20 mL). The 
combined organic layers were dried, filtered and concentrated. The residue was 
purified by flash chromatography (SiO2, Ø 1.5x4 cm, 60% EtOAc/hexanes) and then 
repurified by HPLC (Phenomenex SiO2, Luna Silica(2) 5 µm,  
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20% i-PrOH/hexanes) to afford A17 [37 mg, 0.053 mmol, 67%, white solid, Rf = 0.38  
(60% EtOAc/hexanes), [𝛼]𝐷
25 = + 8.5 (c 0.92, CHCl3)].  
1H NMR (400 MHz, CDCl3): δ 6.4 and 6.0 (d, J = 11.2 Hz, 2H, H-6 and H-7),  
5.32 (s, 1H, H-19), 4.99 (s, 1H, H-19), 4.42 (dd, J = 7.5 and 4.2 Hz, 1H, H-1),  
4.22 (dq, J = 9.5 and 3.3 Hz, 1H, H-3), 2.90 (s, 1H, H-24), 2.81 (dd, J = 12.2 and  
3.6 Hz, 1H), 2.58 (dd, J = 13.3 and 2.7 Hz, 2H), 2.31 (dd, J = 13.4 and 6.4 Hz, 2H), 
2.13 (d, J = 14.8 Hz, 2H), 2.05 – 1.41 (m, 18H), 1.32 – 1.12 (m, 4H), 0.98 (d,  
J = 6.2 Hz, 3H, CH3-21), 0.56 (s, 3H, CH3-18). 
13C NMR (101 MHz, CDCl3): δ 147.8 (C, 
C-10), 142.7 (C, C-8), 133.4 (C, C-5), 124.9 (=CH, C-6), 117.5 (=CH, C-7),  
111.9 (=CH2, C-19), 77.4 (C, C-23), 70.9 (CH, C-1), 67.0 (CH, C-3), 56.5 (CH),  
56.4 (CH), 55.0 (CH, C-24), 45.9 (C, C-13), 45.3 (CH2), 43.2 (CH2), 43.0 (CH2),  
40.4 (CH2), 37.9 (CH), 29.1 (CH2), 27.8 (CH2), 23.6 (CH2), 22.4 (CH2), 20.5 (CH3,  
CH3-21), 12.1 (CH3, CH3-18). IR (film, cm
-1): 3373 (νO-H), 2931, 2851 (νC-H), 2600 (νB-H).  
HRMS ([APCI-TOF]+, m/z) [M+H]+ calcd for C24H45B10O2, 475.4345; found 475.4379. 
 
1-{[(R)-2-((1R,3aS,7aR,E)-4-((Z)-2-((3S,5R)-3,5-dihydroxy-2-
methylenecyclohexylidene)ethylidene]-7a-methyloctahydro-1H-inden-1-
yl)propyl)} -1,12-dicarba-closo-dodecaborane (A33) 
 
A solution of nBuLi (109 µL, 2.5 M, 2 equiv) was added dropwise to a 0 ºC cooled 
solution of p-carborane (39 mg, 0.27 mmol, 2 equiv) in Et2O (3 mL). The bath was 
removed and the cloudy mixture was stirred at rt for 1 h. The reaction mixture was 
cooled to0 ºC and, after 5 min, a solution of 1 (99 mg, 0.14 mmol, 1 equiv) in Et2O  
(2.5 mL) was added via canula. The yellow mixture was stirred in dark at 0 ºC for 2 h. 
Then, the bath was removed and the mixture was stirred overnight at rt. The reaction 
was quenched by addition of H2O (10 mL). The mixture was extracted with MTBE 
(3x10 mL). The combined organic layers were dried, filtered and concentrated. The 
residue was purified by flash chromatography (SiO2, Ø 1.5x6 cm,  
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0-2% EtOAc/hexanes) to give the protected analog 17 [64 mg, 0.091 mmol, 67%,  
Rf = 0.85 (10% EtOAc/hexanes)]. A solution of compound 17 (64 mg, 0.091 mmol,  
1 equiv) in CH2Cl2/CH3CN (4 mL, 1:3) was treated with aqueous HF (48%, 15 drops).  
The mixture was stirred at rt for 2 h and then poured into sat NaHCO3 (50 mL). The 
mixture was stirred for 30 min and then extracted with CH2Cl2 (3x20 mL). The 
combined organic layers were dried, filtered and concentrated. The residue was 
purified by flash chromatography (SiO2, Ø 1.5x6 cm, 60% EtOAc/hexanes) and then 
repurified by HPLC (Phenomenex SiO2, Luna Silica(2) 5 µm, 20% i-PrOH/hexanes) to 
afford A33 [31 mg, 0.066 mmol, 72%, white solid  Rf = 0.50 (60% EtOAc/hexanes), 
[𝛼]𝐷
25 = + 26.7  (c 0.24, CHCl3)].  
1H NMR (400 MHz, CDCl3): δ 6.35 and 5.99 (d, J = 11.2 Hz, 2H, H-6 and H-7), 5.32 (s, 
1H, H-19), 4.98 (s, 1H, H-19), 4.46 – 4.39 (m, 1H, H-1), 4.26 – 4.19 (m, 1H, H-3),  
2.79 (dd, J = 12.2 and 3.6 Hz, 1H), 2.63 (s, 1H, H-24), 2.59 (dd,  
J = 14.0 and 2.7 Hz, 1H), 2.30 (dd, J = 13.4 and 6.4 Hz, 2H), 2.01 (dd,  
J = 13.6 and 7.3 Hz, 2H), 1.96 – 1.86 (m, 4H), 1.84 – 1.70 (m, 3H), 1.63 (d,  
J = 9.2 Hz, 6H), 1.56 – 1.39 (m, 4H), 1.23 (ddd, J = 16.4, 12.7 and 6.8 Hz, 4H), 1.08 (d, 
J = 6.4 Hz, 2H), 0.85 (d, J = 5.4 Hz, 3H, CH3-21), 0.52 (s, 3H, CH3-18).  
13C NMR (101 MHz, CDCl3): δ  147.8 (C, C-10), 142.8 (C, C-8), 133.2 (C, C-5),  
125.0 (=CH, C-6), 117.4 (=CH, C-7), 111.9 (=CH2, C-19), 85.2 (C, C-23), 70.9 (CH,  
C-1), 67.0 (CH, C-3), 58.6 (CH, C-24), 56.5 (CH), 56.3 (CH), 45.9 (C, C-13),  
45.4 (CH2), 45.2 (CH2), 43.0 (CH2), 40.4 (CH2), 37.2 (CH), 29.1 (CH2), 27.7 (CH2),  
23.6 (CH2), 22.3 (CH2), 20.5 (CH3, CH3-21), 12.0 (CH3, CH3-18). IR (film, cm
-1): 3375 
(νO-H), 2916, 2851 (νC-H), 2607 (νB-H). HRMS ([APCI-TOF]
+, m/z) [M+H]+ calcd for 
C24H45B10O2, 475.4345; found 475.4383. 
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1. Docking Results 
1.1. Ortho series 
R n=1 n=2 n=3 
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1.2. Meta series 
R n=1 n=2 n=3 
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1.3. Para series 
R n=1 n=2 n=3 
 
 
  
 
  
 
 
   
96 FCUP | ICBAS | USC 
Appendix  
 
 
 
  
 
 
 
 
 
 
  
 
FCUP | ICBAS | USC 
Appendix 
97 
 
  
 
 
   
 
 
  
98 FCUP | ICBAS | USC 
Appendix  
 
 
 
 
  
 
 
 
 
 
 
  
FCUP | ICBAS | USC 
Appendix 
99 
 
 
  
 
 
 
 
 
  
 
 
 
100 FCUP | ICBAS | USC 
Appendix  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. NMR SPECTRA 
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2. NRM Spectra 
1
H NMR (250 MHz, CDCl3): δ 8.04 (d, J = 7.4 Hz, 2H, Har), 7.55 (dd, J = 8.2 and  
6.4 Hz, 1H, Har), 7.44 (t, J = 7.6 Hz, 2H, Har), 4.31 (dd, J = 10.7 and 3.4 Hz, 1H,  
H-22), 4.06 (dd, J = 10.7 and 7.1 Hz, 2H, H-8 and H-22), 2.04 – 1.20 (m, 14H), 
1.10 (d, J = 6.6 Hz, 3H, CH3-21), 0.99 (s, 3H, CH3-18). 
 
 
 
13
C NMR (63 MHz, CDCl3): δ 166.9 (C, C=O), 132.9 (CH, CHar), 130.7 (C, Car), 129.6 (CH, 2xCHar), 128.5 
(CH, 2xCHar), 70.0 (CH2, C-22), 69.3 (CH, C-8), 53.5 (CH), 52.5 (CH), 42.1 (C, C-13), 40.4 (CH2), 35.7 
(CH), 33.7 (CH2), 26.9 (CH2), 22.71 (CH2), 17.54 (CH2), 17.38 (CH3, CH3-21), 13.71 (CH3, CH3-18). 
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1
H NMR (250 MHz, CDCl3): δ 8.04 – 7.96 (m, 2H, Har), 7.57 – 7.48 (m, 1H, Har), 
7.41 (t, J = 7.4 Hz, 2H, Har), 4.29 (dd, J = 10.8 and 3.4 Hz, 1H, H-22), 4.05 (dd,  
J = 10.8 and 6.8 Hz, 1H, H-22), 2.45 (dd, J = 11.4 and 7.5 Hz, 1H), 2.24 – 1.39 
(m, 12H), 1.12 (d, J = 6.6 Hz, 3H, CH3-21), 0.65 (s, 3H, CH3-18). 
 
 
 
 
13
C NMR (63 MHz, CDCl3): δ 211.7 (C, C=O, C-8), 166.6 (C, C=O), 132.9 (CH, CHar), 130.4 (C, Car), 129.5 
(CH, 2xCHar), 128.4 (CH, 2xCHar), 69.6 (CH2, C-22), 61.6 (CH), 53.4 (CH), 49.9 (C, C-13), 40.9 (CH2), 
38.8 (CH2), 35.8 (CH), 27.0 (CH2), 24.0 (CH2), 19.2 (CH2), 17.4 (CH3, CH3-21), 12.5 (CH3, CH3-18). 
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1
H NMR (250 MHz, CDCl3): δ 8.10 – 8.00 (m, 2H, Har), 7.57 (t, J = 7.3 Hz, 1H, 
Har), 7.45 (t, J = 7.6 Hz, 2H, Har), 5.67 (s, 1H, H-7), 4.33 (dd, J = 10.8 and 3.3 Hz, 
1H, H-22), 4.08 (dd, J = 10.7 and 7.0 Hz, 1H, H-22), 2.90 (dd, J = 10.2 and  
2.8 Hz, 1H), 2.08 – 1.24 (m, 12H), 1.14 (d, J = 6.6 Hz, 3H, CH3-21), 0.62 (s, 3H,  
CH3-18). 
 
 
 
 
13
C NMR (63 MHz, CDCl3): δ 166.8 (C, C=O), 144.9 (C, C-8), 133.0 (CH, CHar), 130.6 (C, Car), 129.7  (CH, 
2xCHar), 128.5 (CH, 2xCHar), 97.8 (CH, C-7), 69.9 (CH2, C-22), 55.7 (CH), 52.7 (CH), 45.8 (C, C-13), 39.9 
(CH2), 36.4 (CH), 31.1 (CH2), 27.3 (CH2), 22.6 (CH2), 22.3 (CH2), 17.6 (CH3, CH3-21), 12.1 (CH3, CH3-18). 
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1
H NMR (250 MHz, CDCl3): δ 8.04 (d, J = 7.0 Hz, 2H, Har), 7.61 – 7.50 (m, 1H, 
Har), 7.44 (t, J = 7.2 Hz, 2H, Har), 4.93 (s, 1H, H-7), 4.32 (dd, J = 9.9 and 2.0 Hz, 
1H, H-22), 4.06 (dd, J = 10.4 and 7.0 Hz, 1H, H-22), 3.19 (d, J = 12.8 Hz, 1H,  
H-14), 2.12 – 1.37 (m, 12H), 1.26 (s, 12H, 4xCH3COB), 1.12 (d, J = 6.4 Hz, 3H, 
CH3-21), 0.60 (s, 3H, CH3-18). 
 
 
 
13
C NMR (63 MHz, CDCl3): δ 166.9 (C, C-8), 165.8 (C=O, Car), 132.9 (CH, CHar), 130.6 (C, Car),  
129.6 (CH, 2xCHar), 128.5 (CH, 2xCHar), 82.7 (C, 2xCH3COB), 70.0 (CH2, C-22), 57.8 (CH, C-7), 53.6 
(CH), 46.4 (C, C-13), 40.4 (CH2), 36.4 (CH, C-20), 33.3 (CH2), 27.1 (CH2), 25.0 (CH3, 2xCH3COB), 24.9 
(CH3, 2xCH3COB), 24.4 (CH2), 22.5 (CH2), 17.6 (CH3, CH3-21), 12.3 (CH3, CH3-18). 
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1
H NMR (250 MHz, CDCl3): δ 8.06 (d, J = 8.0 Hz, 2H, Har), 7.57 (t, J = 6.9 Hz, 
1H, Har), 7.45 (t, J = 7.7 Hz, 2H, Har), 6.25 (d, J = 11.4 Hz, 1H, H-6), 6.04 (d,  
J = 11.1 Hz, 1H, H-7), 5.22 – 5.14 (s, 1H, H-19), 4.87 (s, 1H, H-19),  
4.41 – 4.29 (m, 2H, H-22), 4.25 – 4.14 (m, 1H, H-1), 4.10 – 4.02 (m, 1H, H-3), 
2.90 – 2.78 (m, 1H, H-9), 2.46 (dd, J = 13.1 and 3.3 Hz, 1H, H-4), 2.22 (dd,  
J = 13.1 and 7.2 Hz, 1H, H-4), 1.92 – 1.45 (m, 14H), 1.14 (d, J = 6.4 Hz, 3H, 
CH3-21), 0.90 – 0.81 (m, 18H, 2xCH3CSi), 0.59 (s, 3H, CH3-18), 0.11 – 0.00 (m, 
12H, 4xCH3Si). 
 
 
 
13
C NMR (63 MHz, CDCl3): δ 166.9 (C=O, Car), 148.4 (C, C-10), 140.7 (C, C-8), 135.4 (C, C-5), 133.0 (CH, 
CHar), 130.7 (C, Car), 129.7 (CH, 2xCHar), 128.5 (CH, 2xCHar), 123.2 (=CH, C-6), 118.2 (=CH, C-7), 111.4 
(CH2, C-19), 72.2 (CH, C-1), 70.1 (CH2, C-22), 67.7 (CH, C-3), 56.2 (CH), 53.4 (CH), 46.2 (CH2), 46.0 (C, 
C-13), 44.9 (CH2), 40.6 (CH2), 36.5 (CH), 29.0 (CH2), 27.4 (CH2), 26.0 (CH3, 3xCH3CSi), 25.96 (CH3,  
3xCH3CSi), 23.6 (CH2), 22.4 (CH2), 18.4 (C, CH3CSi), 18.3 (C, CH3CSi), 17.7 (CH3, CH3-21), 12.2 (CH3,  
CH3-18), -4.5 (CH3, 2xCH3Si), -4.6 (CH3, CH3Si), -4.9 (CH3, CH3Si). 
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1
H NMR (250 MHz, CDCl3): δ 6.24 (d, J = 11.3 Hz, 1H, H-6), 6.02 (d,  
J = 11.2 Hz, 1H, H-7), 5.18 (s, 1H, H-19), 4.86 (s, 1H, H-19), 4.37 (dd, J = 6.3 
and 3.8 Hz, 1H, H-1), 4.19 (ddd, J = 10.8, 7.2 and 3.8 Hz, 1H, H-3), 3.65 (dd,  
J = 10.5 and 3.0 Hz, 1H, H-22), 3.38 (dd, J = 10.5 and 6.7 Hz, 1H, H-22),  
2.87 – 2.77 (m, 1H, H-9), 2.44 (dd, J = 13.0 and 3.3 Hz, 1H), 2.21 (dd,  
J = 13.0 and 7.1 Hz, 1H, H-4), 2.03 – 1.24 (m, 15H), 1.05 (d, J = 6.5 Hz, 3H, 
CH3-21), 0.88 (s, 18H, 2x CH3CSi), 0.55 (s, 3H, CH3-18), 0.06 (s, 12H, 4x CH3Si). 
 
 
 
 
13
C NMR (63 MHz, CDCl3): δ 148.5 (C, C-10), 140.9 (C, C-8), 135.3 (C, C-5), 123.2 (=CH, C-6), 118.1 
(=CH, C-7), 111.3 (=CH2, C-19), 72.2 (CH, C-1), 68.1 (CH2, C-22), 67. 7 (CH, C-3), 56.2 (CH), 52.9 (CH), 
46.2 (CH2), 46.0 (C, C-13), 44.9 (CH2), 40.6 (CH2), 39.24 (CH), 29.0 (CH2), 27.4 (CH2), 26.00  
(CH3, 3xCH3CSi), 25.96 (CH3, 3xCH3CSi), 23.6 (CH2), 22.4 (CH2), 18.4 (C, CH3CSi), 18.3 (C, CH3CSi), 
17.0 (CH3, CH3-21), 12.2 (CH3, CH3-18), -4.5 (CH3, 2xCH3Si), -4.6 (CH3, CH3Si),  -4.9 (CH3, CH3Si). 
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1
H NMR (250 MHz, CDCl3): δ 7.79 (d, J = 8.3 Hz, 2H, Har), 7.34 (d, J = 8.4 Hz, 
2H, Har), 6.22 (d, J = 11.3 Hz, 1H, H-6), 5.99 (d, J = 11.6 Hz, 1H, H-7), 5.17  
(s, 1H, H-19), 4.84 (s, 1H, H-19), 4.36 (dd, J = 6.5 and 4.1 Hz, 1H, H-1),  
4.24 – 4.12 (m, 1H, H-3), 3.97 (dd, J = 9.2 and 2.9 Hz, 1H, H-22), 3.79 (dd,  
J = 9.2 and 6.3 Hz, 1H, H-22), 2.85 – 2.75 (m, 1H), 2.51 – 2.39 (m, 3H), 2.20 (dd,  
J = 13.2 and 6.9 Hz, 2H), 2.03 – 1.06 (m, 17H), 1.01 – 0.79 (m, 18H, 2xCH3CSi), 
0.49 (s, 3H, CH3-18), 0.05 (s, 12H, 4xCH3Si). 
 
 
 
 
13
C NMR (63 MHz, CDCl3): δ 148.5 (C, C-10), 144.7 (C, Car), 140.4 (C, C-8), 135.5 (C, C-5), 133.2  
(C, Car), 129.9 (2xCH, Car), 128.1 (2xCH, Car), 123.1 (=CH, C-6), 118.3 (=CH, C-7), 111.3 (=CH2, C-19), 
75.7 (CH2, C-22), 72.2 (CH, C-1), 67.6 (CH, C-3), 56.0 (CH), 52.3 (CH), 46.1 (C, C-13), 45.9 (CH2), 44.9 
(CH2, C-2), 40.4 (CH2, C-12), 36.7 (CH), 28.9 (CH2), 27.1 (CH2), 25.99 (CH3, 3xCH3CSi), 25.96 (CH3, 
3xCH3CSi), 23.5 (CH2), 22.2 (CH2), 21.8 (CH3, CH3-Ts), 18.37 (C, CH3CSi), 18.30 (C, CH3CSi), 17.1 (CH3, 
CH3-21), 12.1 (CH3, CH3-18), -4.5 (CH3, 2xCH3Si), -4.6 (CH3, CH3Si), -4.9 (CH3, CH3Si). 
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1
H NMR (400 MHz, CDCl3): δ 6.35 and 6.01 (d, J = 11.2 Hz, 2H, H-6 and H-7), 
5.33 (s, 1H, H-19), 4.99 (s, 1H, H-19), 4.43 (dd, J = 7.7 and 4.2 Hz, 1H, H-1),  
4.23 (dq, J = 9.5 and 3.3 Hz, 1H, H-3), 3.53 (s, 1H, H-24), 2.82 (dd, J = 12.2 and 
3.7 Hz, 1H), 2.59 (dd, J = 13.4 and 2.8 Hz, 1H), 2.36 – 2.28 (m, 3H), 2.07 – 1.78 
(m, 11H), 1.73 – 1.58 (m, 7H), 1.50 (dd, J = 18.9 and 9.8 Hz, 3H), 1.31 – 1.16 (m, 
5H), 1.04 (d, J = 6.3 Hz, 3H, CH3-21), 0.58 (s, 3H, CH3-18). 
 
 
 
 
13
C NMR (63 MHz, CDCl3): δ 147.8 (C, C-10), 142.3 (C, C-8), 133.6 (C, C-5), 124.9 (=CH, C-6),  
117.6 (=CH, C-7), 111.9 (=CH2, C-19), 75.7 (C, C-23), 70.8 (CH, C-1), 67.0 (CH, C-3), 62.2 (CH, C-24), 
56.5 (CH), 56.2 (CH, 45.9 (C, C-13), 45.3 (CH2, C-4), 44.5 (CH2), 43.0 (CH2), 40.4 (CH2), 37.7 (CH),  
29.0 (CH2), 28.0 (CH2), 23.5 (CH2), 22.3 (CH2), 20.6 (CH3, CH3-21), 12.1 (CH3, CH3-18).  
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11
B NMRdec (160 MHz, CDCl3): δ -2.27, -5.59, -9.31, -11.64, -13.13. 
 
 
11
B NMRac (160 MHz, CDCl3): δ -1.32, -2.24, -4.68, -5.53, -8.35, -9.29, -11.96, -13.13. 
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1
H NMR (400 MHz, CDCl3): δ 6.4 and 6.0 (d, J = 11.2 Hz, 2H, H-6 and H-7),  
5.32 (s, 1H, H-19), 4.99 (s, 1H, H-19), 4.42 (dd, J = 7.5 and 4.2 Hz, 1H, H-1),  
4.22 (dq, J = 9.5 and 3.3 Hz, 1H, H-3), 2.90 (s, 1H, H-24), 2.81 (dd, J = 12.2 and 
3.6 Hz, 1H), 2.58 (dd, J = 13.3 and 2.7 Hz, 2H), 2.31 (dd, J = 13.4 and 6.4 Hz, 
2H), 2.13 (d, J = 14.8 Hz, 2H), 2.05 – 1.41 (m, 18H), 1.32 – 1.12 (m, 4H), 0.98 (d,  
J = 6.2 Hz, 3H, CH3-21), 0.56 (s, 3H, CH3-18). 
 
 
 
 
13
C NMR (101 MHz, CDCl3): δ 147.8 (C, C-10), 142.7 (C, C-8), 133.4 (C, C-5), 124.9 (=CH, C-6),  
117.5 (=CH, C-7), 111.9 (=CH2, C-19), 77.4 (C, C-23), 70.9 (CH, C-1), 67.0 (CH, C-3), 56.5 (CH),  
56.4 (CH), 55.0 (CH, C-24), 45.9 (C, C-13), 45.3 (CH2), 43.2 (CH2), 43.0 (CH2), 40.4 (CH2), 37.9 (CH), 
29.1 (CH2), 27.8 (CH2), 23.6 (CH2), 22.4 (CH2), 20.5 (CH3, CH3-21), 12.1 (CH3, CH3-18). 
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11
B NMRdec (160 MHz, CDCl3): δ -3.79, -10.73, -13.69, -15.14. 
 
11
B NMRac (160 MHz, CDCl3): δ -2.72, -3.69, -9.68, -10.62, -12.60, -13.69, -15.14. 
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1
H NMR (400 MHz, CDCl3): δ 6.35 and 5.99 (d, J = 11.2 Hz, 2H, H-6 and H-7), 
5.32 (s, 1H, H-19), 4.98 (s, 1H, H-19), 4.46 – 4.39 (m, 1H, H-1), 4.26 – 4.19 (m, 
1H, H-3), 2.79 (dd, J = 12.2 and 3.6 Hz, 1H), 2.63 (s, 1H, H-24), 2.59 (dd,  
J = 14.0 and 2.7 Hz, 1H), 2.30 (dd, J = 13.4 and 6.4 Hz, 2H), 2.01 (dd,  
J = 13.6 and 7.3 Hz, 2H), 1.96 – 1.86 (m, 4H), 1.84 – 1.70 (m, 3H), 1.63 (d,  
J = 9.2 Hz, 6H), 1.56 – 1.39 (m, 4H), 1.23 (ddd, J = 16.4, 12.7 and 6.8 Hz, 4H), 
1.08 (d, J = 6.4 Hz, 2H), 0.85 (d, J = 5.4 Hz, 3H, CH3-21), 0.52 (s, 3H, CH3-18). 
 
 
 
13
C NMR (101 MHz, CDCl3): δ  147.8 (C, C-10), 142.8 (C, C-8), 133.2 (C, C-5), 125.0 (=CH, C-6), 117.4 
(=CH, C-7), 111.9 (=CH2, C-19), 85.2 (C, C-23), 70.9 (CH, C-1), 67.0 (CH, C-3), 58.6 (CH, C-24), 56.5 
(CH), 56.3 (CH), 45.9 (C, C-13), 45.4 (CH2), 45.2 (CH2), 43.0 (CH2), 40.4 (CH2), 37.2 (CH), 29.1 (CH2), 
27.7 (CH2), 23.6 (CH2), 22.3 (CH2), 20.5 (CH3, CH3-21), 12.0 (CH3, CH3-18). 
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11
B NMRdec (160 MHz, CDCl3):δ  -12.34, -15.17. 
 
11
B NMRac (160 MHz, CDCl3): δ -11.84, -12.86, -14.66, -15.69. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. IR SPECTRA 
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3. IR Spectra 
 
IR (film, cm
-1
): 3533 (νO-H), 2941 (νC-Har), 2873 (νC-Har), 1718 (νC=O), 1450, 1273, 1117, 711 
 
 
 
IR (film, cm
-1
): 2962 (ν), 2873 (ν), 1714 (ν), 1387, 1313, 1273, 1111, 1070, 1026, 714 
 
 
IR (film, cm
-1
): 2947 (ν), 2870 (ν), 1718 (ν), 1450 (ν), 1273, 1111, 712 
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IR (film, cm
-1
): 2980 (νC-H), 2870 (νC-H), 1718 (ν), 1639 (νc=c), 1452, 1390, 1340, 1271, 1146, 1107, 966, 
868, 852, 711 
 
 
 
 
IR (film, cm
-1
): 2918 (νC-H), 2849 (νC-H), 1724 (ν), 1472, 1271, 1082, 835, 775, 710 
 
 
 
 
IR (film, cm
-1
): 3358 (νO-H), 2918 (νC-H), 2847 (νC-H), 1657 (ν), 1634, 1472, 1074, 833, 775 
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IR (film, cm
-1
): 2953, 2924 (νC-H), 2851 (νC-H), 1472, 1364, 1254, 1178, 1074, 962, 908, 835, 775, 667, 557 
 
 
IR (film, cm
-1
): 3361 (νO-H), 2955, 2918 (νC-H), 2849 (νC-H), 2594 (νB-H), 1462 
 
 
 
 
IR (film, cm
-1
): 3373 (νO-H), 2931, 2851 (νC-H), 2600 (νB-H) 
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IR (film, cm
-1
): 3375 (νO-H), 2916, 2851 (νC-H), 2607 (νB-H) 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. STRUCTURE INDEX 
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4. Structure Index 
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